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Abstract: Therapy of acute myeloid leukemia (AML) is unsatisfactory. Histone deacetylase inhibitors
(HDACi) are active against leukemic cells in vitro and in vivo. Clinical data suggest further testing
of such epigenetic drugs and to identify mechanisms and markers for their efficacy. Primary and
permanent AML cells were screened for viability, replication stress/DNA damage, and regrowth
capacities after single exposures to the clinically used pan-HDACi panobinostat (LBH589), the
class I HDACi entinostat/romidepsin (MS-275/FK228), the HDAC3 inhibitor RGFP966, the HDAC6
inhibitor marbostat-100, the non-steroidal anti-inflammatory drug (NSAID) indomethacin, and the
replication stress inducer hydroxyurea (HU). Immunoblotting was used to test if HDACi modulate
the leukemia-associated transcription factors β-catenin, Wilms tumor (WT1), and myelocytomatosis
oncogene (MYC). RNAi was used to delineate how these factors interact. We show that LBH589,
MS-275, FK228, RGFP966, and HU induce apoptosis, replication stress/DNA damage, and apoptotic
fragmentation of β-catenin. Indomethacin destabilizes β-catenin and potentiates anti-proliferative
effects of HDACi. HDACi attenuate WT1 and MYC caspase-dependently and -independently. Genetic
experiments reveal a cross-regulation between MYC and WT1 and a regulation of β-catenin by WT1.
In conclusion, reduced levels of β-catenin, MYC, and WT1 are molecular markers for the efficacy of
HDACi. HDAC3 inhibition induces apoptosis and disrupts tumor-associated protein expression.
Keywords: AML; β-catenin; HDAC; HDACi; indomethacin; molecular marker; MYC; WT1
1. Introduction
It is estimated that there will be 437,033 new cases of leukemia and 309,006 deaths associated
worldwide in 2018 [1]. Predictions state that more than 21,450 people will be diagnosed with acute
myeloid leukemia (AML) and nearly 10,920 people will die from it alone in the USA in 2019 [2].
This warrants the search for new therapeutic strategies. The transcription factor β-catenin appears
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as an actionable drug target in AML, because the expression and activity of β-catenin is linked
to disease initiation, unfavorable karyotypes, and poor prognosis. Cells from such patients show
enhanced self-renewal capacity, which suggests thatβ-catenin contributes to a stemness phenotype [3–9].
Moreover, β-catenin is expressed at significantly higher levels in AML compared to acute lymphoblastic
leukemia and β-catenin was found to be overexpressed in 16/25 and 13/59 primary AML samples [5,6].
Furthermore, a recent report illustrates that β-catenin is important for chemotherapy-associated
senescence and contributes to aggressive growth patterns of leukemia and lymphoma cells [10].
However, patient-to-patient variations regarding the addiction of AML cells to β-catenin [4,5,11]
demonstrate the need to further characterize how β-catenin affects leukemogenesis.
Secreted factors of the wingless-type MMTV integration site (WNT) family stabilize β-catenin.
They reduce the phosphorylation of β-catenin and its subsequent poly-ubiquitylation for proteasomal
degradation. Consequently, β-catenin accumulates in the nucleus, where it induces genes in complex
with the transcription factor, T cell factor-4 [12,13]. In AML cells, a cell-intrinsic activation of β-catenin
can render leukemic stem cells independent of niche-derived WNT signals [14]. Factors that are
responsible for the proteasomal degradation ofβ-catenin include the glycogen synthase kinase-3 (GSK3),
the adapter adenomatous polyposis coli, E3 ubiquitin ligases such as seven-in-absentia-homologues-1/-2,
F-box/WD repeat-containing protein 1A, and other proteins [15]. In addition to this proteasomal
pathway, β-catenin can be cleaved by caspases [16,17].
Current research strives to identify and exploit epigenetic mechanisms for the therapy of solid
tumors and leukemia. A dysregulation of histone deacetylases (HDACs) is seen in leukemic cells
and four Histone deacetylase inhibitors (HDACi; LBH589, FK228, vorinostat (SAHA), and belinostat
(PXD101)) have been approved by the FDA for the treatment of hematological disorders. Moreover,
there are currently at least 15 HDACi in clinical trials [18,19]. The development of specific HDACi aims
to define and exploit individual functions of HDACs in vivo and to reduce adverse effects of HDACi
treatment [18,20,21]. Clinically used HDACi encompass small molecules that inhibit all zinc-dependent
HDACs or HDAC subclasses ([18,19] and http://www.clinicaltrials.org). For example, the hydroxamic
acid LBH589 blocks zinc-dependent HDACs that belong to class I (HDAC1, -2, -3, and -8), class II
(HDAC4, -5, -6, -7, -9, and -10), and class IV (HDAC11). The benzamide MS-275 and the depsipeptide
FK228 act only against the class I HDACs HDAC1, -2, and -3 [22].
A recent report shows that the anthraquinone oxime-analog BC2059 attenuates the expression of
β-catenin in AML cells with and without an internal tandem duplication of the leukemogenic kinase
FMS-like tyrosine kinase (FLT3-ITD) through a proteasomal mechanism. This mechanism involves a
displacement of the scaffold protein transducin β-like-1 from β-catenin [23]. This work also indicates
that LBH589 and BC2059 combine favorably against AML cells and that this effect is associated with
a reduction of β-catenin [23]. However, it has not been addressed how HDACi decrease β-catenin,
whether the attenuation of β-catenin by HDACi is a key factor for the fate of AML cells, and if one
of the 11 zinc-dependent mammalian HDACs controls β-catenin expression. One of these HDACs
might be the class IIB deacetylase HDAC6, because the tubulin polymerization promoting protein-1
blocks HDAC6 and attenuates β-catenin expression [24]. Furthermore, HDAC6 interacts with the
cancer stem cell marker membrane glycoprotein CD133 and both were reported to stabilize β-catenin
acetylation-dependently [25]. However, a key impact of HDAC6 on an important developmental
regulator like β-catenin [12,13] is hard to reconcile with the lack of phenotypic abnormalities in HDAC6
knockout mice and with accumulating evidence that an inhibition of HDAC6 does not affect cancer
cell growth [26–29]. HDACi that preferentially target HDAC3 evoke a destabilization of β-catenin,
but not its mRNA expression, in breast cancer cells [30]. Therefore, HDAC3 could be a key positive
regulator of β-catenin stability in leukemic cells.
There is evidence that non-steroidal anti-inflammatory drugs (NSAIDs), which inhibit the
immunomodulatory enzymes cyclooxygenase-1/cyclooxygenase-2 (COX1/COX2), antagonizeβ-catenin
expression and the stemness of leukemic cells [31–34]. Moreover, data collected with cells from various
solid tumors suggest that a combined application of indomethacin with pan-HDACi as single or
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bifunctional molecules suppresses cell proliferation and angiogenesis. Remarkably, normal cells are
spared by such treatment [35,36]. Whether NSAIDs combine favorably with HDACi against leukemic
cells is an interesting option that remains to be investigated.
The transcription factor myelocytomatosis oncogene (MYC), which has been implicated in
maintaining the stemness of AML cells [13,37,38], can be a target gene of β-catenin in leukemic
cells [23,39,40]. Pan- and class I HDACi provoke a downregulation of MYC in cancer cells [19,23,41–44].
In addition to β-catenin and MYC, the transcription factor Wilms tumor (WT1) is associated with
cell differentiation and leukemogenesis [45], and, like β-catenin and MYC, WT1 is regulated by
HDACi [46]. Furthermore, WT1 can regulate the expression of MYC and of β-catenin positively and
negatively [47–54]. It is currently not clear if there is a mutual regulation of these factors in leukemic
cells and whether HDACi alter a potential interplay between these three transcription factors.
In order to fully develop the therapeutic potential of HDACi, some key questions need to be
resolved. For example, 18 human HDACs fall into the classes I, II, III, and IV and it has to be further
clarified if a pharmacological inhibition of subsets or even single HDACs can produce anti-leukemic
effects. Moreover, further molecular mechanisms and markers have to be identified to use HDACi
effectively. We set out to answer these questions. Our data demonstrate that HDAC3 activity is a key
factor for the survival and the maintenance of tumor- and stemness-associated transcription factors in
AML cells.
2. Results
2.1. Responses of Leukemic Cells to LBH589
We analyzed the responses of human AML cell lines (FLT3-ITD-positive MV4-11 and
JAK2V617F-positive HEL cells) to the pan-HDACi LBH589. We noted a significant time- and
dose-dependent accumulation of annexin-V-FITC-positive cells. After 24 h, 10 nM LBH589 induced
a three-fold increase in annexin-V-FITC-positive MV4-11 cells, which corresponds to 16% apoptotic
cells. 30 nM LBH589 caused a four-fold increase of apoptosis in MV4-11 cells and a six-fold increase
of apoptotic cells in HEL cells, which corresponds to 34% and 67% dead cells (Figure 1A; see
Supplementary Figure S1 for exemplary dot plots).
After 48 h, 10 nM LBH589 sufficed to induce 78% annexin-V-positive cells in MV4-11 cell cultures
and 30 nM LBH589 led to 78% annexin-V-positive cells in HEL cell cultures (Supplementary Figure S2).
The analysis of the cell cycle distributions of LBH589-treated cells revealed that 10 nM LBH589
significantly increased the number of MV4-11 cells in the G1 phase by 20% and reduced the number of
S phase cells by 18%. Such changes also occurred in HEL cells as a trend. 30 nM LBH589 augmented
the subG1 fraction, which represents cells with fragmented DNA, by 23% in MV4-11 and by 30% in
HEL cell cultures (Figure 1B). These increased levels of the subG1 fractions were linked to a decline of
the G1 and S phase populations in both cell lines and 30 nM LBH589 reduced the number of HEL cells
in S phase significantly by 9% (Figure 1B).
In both cell types, the novel and specific HDAC6 inhibitor marbostat-100 [26] caused a slight and
insignificant increase in their G1 phase populations at the expense of S phase populations. Marbostat-100
did not induce apoptosis in MV4-11 and HEL cell cultures (Figure 1A,B and Supplementary Figure S1).
Thus, pro-apoptotic effects of LBH589 are unlikely caused by its inhibitory effect on HDAC6.
To corroborate these results, we analyzed further apoptosis markers, the cleavage of the executioner
caspase-3 and the caspase-dependent cleavage of PARP1 [29,55]. Congruent with our flow cytometry
analyses, we detected significant caspase-3 activation and cleaved PARP1 in MV4-11 and HEL cells
incubated with 30 nM LBH589 for 24 h (Figure 1C). Compared to HEL cells, MV4-11 cells have much
lower levels of PARP1, which are more evident as cleaved PARP1 in apoptotic MV4-11 cells. It is
currently unknown whether HDACi induce PARP1 that is subsequently cleaved or if our antibodies
recognize cleaved PARP1 better than its full-length form.
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and 1 µM) for 24 h. Cells were stained with annexin-V-FITC/propidium iodide (PI) and analyzed by 
flow cytometry (n = 3; mean + SD; two-way ANOVA; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001). 
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Figure 1. Human leukemia cell lines are sensitive against LBH589. (A) Human MV4-11 and HEL cells
were treated with 10 to 30 nM LBH589 or increasing doses of marbostat-100 (M-100; 50 nM, 500 nM,
and 1 µM) for 24 h. Cells were stained with annexin-V-FITC/propidium iodide (PI) and analyzed by
flow cytometry (n = 3; mean + SD; two-way ANOVA; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001).
(B) Cells were incubated with HDACi as stated in (A). Fixed cells were stained with PI and cell cycle
distributions were analyzed by flow cytometry (n = 3; mean + SD; two-way ANOVA; * p ≤ 0.05;
** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001). (C) Cells were treated with 10 nM or 30 nM LBH589 for 24 h.
Indicated proteins were detected via Western blot (cl., cleaved; fl., full-length) with HSP90 and β-actin
as loading controls (n = 3). Please note that compared to HEL cells MV4-11 cells have far less full-length
PARP1 and that the lot of the anti-PARP1 antibody may have preferentially recognized the cleaved
form of PARP1. (D) Regrowth of the human leukemia cell lines MV4-11 and HEL. Cells were treated
with 10 nM or 30 nM LBH589 for 24 h. Thereafter, cells were washed twice with PBS and reseeded.
Cells were stained with trypan blue and viable cells were counted after 4 days (n = 3; mean + SD;
one-way ANOVA; **** p ≤ 0.0001).
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We additionally analyzed the ability of these cells to regrow at low density once the treatment
with HDACi had been stopped. We treated MV4-11 and HEL cells with 10 or 30 nM LBH589 for 24 h.
Thereafter, the cells were harvested and washed twice for withdrawal of HDACi. The proliferation of
the cells was determined at day 4 after discontinuation of the treatment. Regrowth of MV4-11 was
nearly prevented by 10 nM LBH589 and HEL cells were unable to regrow after an exposure to 30 nM
LBH589 (Figure 1D).
These data indicate that low levels of LBH589 mainly promote cell cycle arrest and higher doses
lead to the induction of apoptosis and the fragmentation of DNA in MV4-11 and HEL cell cultures.
2.2. Reduction of β-Catenin upon Class I HDAC Inhibition
Since β-catenin is relevant for the growth and survival of leukemic cells [3–9], we tested whether
LBH589 alters the expression of this protein in leukemic cells. Western blot analyses of MV4-11 and
HEL cells revealed that β-catenin was significantly degraded after incubation with LBH589. This led to
the advent of an additional band that was revealed by theβ-catenin antibody (Figure 2A). Theβ-catenin
mRNA levels were not decreased by LBH589 (data not shown).
As LBH589 blocks class I, II, and IV HDACs [22], we addressed whether class I HDACs and/or
HDAC6 prevent the processing of β-catenin. We inhibited HDAC1-3 with MS-275 [22] and HDAC6
with marbostat-100 [26]. We noticed that MS-275 caused the cleavage of PARP1 and β-catenin together
with an activation of caspase-3 in both cell lines (Figure 2A). LBH589 and MS-275 also promoted an
accumulation of
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H2AX indicating replication stress and/or DNA damage [21] in MV4-11 and HEL
cells (Figure 2A). We could confirm [26] that LBH589 attenuates the expression of HDAC6 in leukemic
cells. Moreover, LBH589 as well as marbostat-100 effectively inhibit HDAC6, which is evident as
accumulation of acetylated tubulin [26,28,29]. Congruent with Figure 1A,B, marbostat-100 did not
evoke the activation of caspase-3 or the processing of β-catenin (Figure 2A).
To exclude that the processing of β-catenin in response to HDACi is an artifact of permanent
leukemic cell cultures, we incubated the LTC FFM12 with LBH589. As in permanent cell lines, LBH589
led to a cleavage of β-catenin and PARP1 (Figure 2B).
Next, we compared the β-catenin levels of MV4-11 and HEL cells with the β-catenin levels in
normal PBMCs. We included colorectal cancer cells with wild-type (RKO cells) or mutant β-catenin
(HCT116 cells) for comparison. We found a similar expression of β-catenin in PBMCs, RKO, HEL, and
MV4-11 cells. HCT116 cells showed the expected [56] overexpression of mutant β-catenin (Figure 2C).
These data suggest that β-catenin is wild-type in MV4-11 and HEL cells.
We noted the occurrence of β-catenin cleavage products in cells with a high activity of the
apoptosis executioner enzyme caspase-3 (Figure 2A), which can cleave β-catenin [16,17]. Therefore,
we speculated that caspases process β-catenin in AML cells exposed to pro-apoptotic doses of LBH589.
We tested this hypothesis with the pan-caspase inhibitor z-VAD-FMK. Incubation of AML cells with
LBH589 and z-VAD-FMK prevented the occurrence of β-catenin cleavage products and restored
the levels of full-length β-catenin (Figure 2D). We observed similar data for MS-275 and FK228 and
the efficiency of z-VAD-FMK was proven as abrogated activation of caspase-3 and intact PARP1
(Supplementary Figure S3).
To complement these analyses, we tested for putative alterations of the expression and
phosphorylation-dependent activation of GSK3β, which pro otes the proteasomal degradation
of β-catenin [15]. We noted that HDACi do not alter total and phosphorylated GSK3β in MV4-11 and
FFM12 cells (Figure 2B,D).
LBH589, MS-275, and FK228 increased the levels of
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cells (Figure 2A, and Supplementary Figure S3). DNA double strand breaks, which are generated upon
DNA fragmentation by caspase-activated DNase, can also induce
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promoted an accumulation of   ɣ   H2AX indicating replication stress and/or DNA damage [21] in 
MV4-11 and HEL ce ls (Figure 2A). We c ld confirm [26] that LBH589 attenuates the expression of 
HDAC6 i  leukemic cells. Moreover, LBH589 as well as marbostat-100 effectively inhibit HDAC6, 
which is evid nt as accumulation of acetylated tubulin [26,28,29]. Congruent with Figure 1A,B, 
marbostat-100 did n t evoke the activa ion of caspase-3 or the processing of β-catenin (Figure 2A).  
To exclud that the processing of β-catenin in response to HDACi is an artifact of permanent 
leukemic cell cultures, we incubated the LTC FFM12 with LBH589. As in permanent cell lines, 
LBH589 led to a cleavage of β-catenin and PARP1 (Figure 2B). 
Next, we compared the β-caten n levels of MV4-11 and HEL cells with the β-catenin levels in 
normal PBMCs. W  included colorectal cancer cells with wild-type (RKO cells) or mutant β-catenin 
(HCT116 cells) for compar son. We found a similar expression of β-catenin in PBMCs, RKO, HEL, 
and MV4-11 ells. HCT116 cells show d the xpected [56] overexpression of mu an  β-catenin (Figure 
2C). These data suggest th t β-catenin is wild-type in MV4-11 and HEL cells. 
We noted the occurrence of β-cate in cleavage products in cells with a high activity of the 
apoptosis executioner enzyme caspase-3 (Figure 2A), which can cleave β-caten n [16,17]. Therefore, 
we specul ted that caspases process β-catenin in AML cells exposed to pro-apoptotic doses of 
LBH589. We tested this hypothesis with the pan-caspa  inhibitor z-VAD-FMK. Incubation of AML 
cells with LBH589 and z-VAD-FMK prevented the occurrence of β-catenin cleavage products and 
restored the levels of full-length β-catenin (Figure 2D). We observed similar data for MS-275 and 
FK228 and he fficie cy of z-VAD-FMK was roven as abrogated activation of caspase-3 and intact 
PARP1 (Su plementary Figure S3). 
To c mplement these analyses, we tested for putative alterations of the expression and 
phospho ylation-dependent activation of GSK3β, which promotes the proteasomal degradation of β-
catenin [15]. We noted that HDACi do not alter total hosphorylated GSK3β in MV4-11 and 
FFM12 cells (Figur  2B,D). 
LBH589, MS-275, nd FK228 increased the levels of ɣH2AX and promoted apoptosis of MV4-11 
cells (Figure 2A, and Supplement ry Figure S3). DNA d uble strand breaks, which ar  generated 
upon DNA fragmentation by caspase-activated DNase, can also induce ɣH2AX [57,58]. Therefore, 
s ch a  accumulation of ɣH2AX might be a consequence of apoptotic DNA fragmentation. To test 
this, we incubated MV4-11 cells with HDACi and z-VAD-FMK. We found tha  this accumulation of 
ɣH2AX could only be partially abrogated with z-VAD-FMK (Supplementary Figure S3). These data 
agree with previous reports indicating that HDACs are gatekeepers of genomic integrity [21,28,59–
61]. 
H2AX [57,58]. Therefore, such an
accumulation of
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0.01; *** p ≤ 0.001; **** p ≤ 0.0001). (C) Cells were trea ed with 10 nM r 30 nM LBH589 for 24 h. 
Indicated proteins were detected via Western blot (cl., cleave ; fl., full-leng h) wit  HSP90 and β-actin 
as loading controls (n = 3). Please note that compared to HEL cells MV4-11 cells have far l ss full-
length PARP1 and that the lot of the anti-PARP1 a tibody may have preferentially recog ized the 
cleaved form of PARP1. (D) Regrowth of the huma  leukemia cell lines V4-11 a d HEL. Cells were 
treated with 10 nM or 30 nM LBH589 for 24 h. Thereafter, cells were washed twice with PBS and 
reseeded. Cells were stained with trypan blue and viable cells were counted after 4 days (n = 3; mean 
+ SD; one-way ANOVA; **** p ≤ 0.0001). 
2.2. Reduction of β-Catenin upon Class I HDAC Inhibition 
Since β-catenin is relevant for the gr th nd survival of leuk mic c lls [3–9], we tested whether
LBH589 alters the expression of this protein leukemic c ls. Western blot nalyses of MV4-11 and 
HEL cells revealed tha  β-cate in wa  significantly degraded after incubation with LBH589. This le
to the adven  f an additional band that was reve l d by the β-catenin antibody (Figu 2A). The
mRNA levels were not decreased by LB 589 (d ta not shown). 
As LBH589 blocks class I, II, and IV HDACs [22], we addressed whether class I HDACs and/or 
HDAC6 prevent the processing of β-catenin. We inhibited HDAC1-3 with MS- 75 [22] and HDAC6
with marbostat-100 [26]. We no iced that MS-275 caused e cleavage of PARP1 nd β-catenin
together with an activation of caspase-3 in both c ll lines (Figure 2A). LBH589 and MS-275 also
promoted an accumulation of   ɣ   H2AX indicating replication stress a d/or DNA d mage [21] in
MV4-11 and HEL cells (Figure 2A). We could confirm [26] that LBH589 ttenua s the express
HD C6 in eukemic cells. Moreover, LBH589 as well as marbos at-100 effectively i hib t HDAC6,
which is evident as accumulat on of acetylated tu ulin [26,28,29]. Congruent with F gure 1A,B, 
marbostat-100 did not evoke the activation of caspase-3 or the processing of β-cate in (Figure 2A).  
To exclude that the processing of β-catenin in r spons  to HDACi is a  artif ct of permane t 
leukemic cell cultures, we incubated the LTC FFM12 with LBH589. As in perma ent cell lines, 
LBH589 led to a cleavage of β-catenin and PARP1 (Figure 2B). 
Next, we compared the β-catenin levels of MV4-11 and HEL cells with the β-ca nin levels in 
normal PBMCs. We included colorectal cancer cells with wild-type (RKO cells) or muta t β-catenin 
(HCT116 cells) for comparison. We found a similar expr ssion of β-catenin in PBMCs, RKO, HEL, 
and MV4-11 cells. HCT116 cells showed the expect d [56] v expression of mutant β-catenin (Figure 
2C). These data suggest that β-catenin is wild-type in MV4-11 and HEL cells. 
We noted the occurrence of β-catenin cleavage products in cells with a high ctivity of the 
apoptosis executioner enzyme caspase-3 (Figure 2A), which can cleave β-catenin [16,17]. Th refo ,
we speculated that caspases process β-catenin in AML c lls exposed to pro-apoptotic doses of
LBH589. We tested this hypothesis with the pa -caspase inhibitor z- F . Incubation of AML 
cells with LBH589 and z-VAD-FMK prevented the ccurrenc of β-catenin cleavage products and
restored the levels of full-length β-catenin (Figure 2D). We observed similar data for MS-275 and 
FK228 and the efficiency of z-VAD-FMK was proven as abrogated activation of caspase-3 and intact 
PARP1 (Supplementary Figure S3). 
To complement these analyses, we tested f r putative alt rations of the expression and 
phosphorylation-dependent activation of GSK3β, which promotes the proteasomal degradation of β-
catenin [15]. We noted that HDACi do not alter total and phosphoryla ed GSK3β in MV4-11 and 
FFM12 cells (Figure 2B,D). 
LBH589, MS-275, and FK228 increased the levels of ɣH2AX and promot d apoptosi  of MV4-11
cells (Figure 2A, and Supplementary Figure S3). DNA ouble stra d breaks, which are generated 
upon DNA fragmentation by caspase-activated DNase, can also nduce ɣ 2 X [57,58]. Therefor , 
such an accumulation of ɣH2AX might be a consequ nce of a ptotic DNA fragmentation. To test 
this, we incubated MV4-11 cells with HDACi and z-VAD-FMK. We found that this accumula ion of 
ɣH2AX could only be partially abrogated with z-VAD-FMK (Supplem ntary Figure S3). These data 
agree with previous reports indicating that HDACs are gatekeepers of genomic integrity [21,28,59–
61]. 
H2AX might be a consequence of apoptotic D A fragmentation. To test this, we
incubated MV4-11 cells with HDACi and z-VAD-FMK. We found that this accumulation of
Cancers 2019, 11, x 5 of 20 
0.01; *** p ≤ 0.001; **** p ≤ 0.0001). (C) Cells were tre ted with 10 nM or 30 nM LBH589 for 24 h. 
Indic ted proteins w re detected via Weste n blot (cl., cleaved; fl., full-length) with HSP90 and β-actin 
as l ading controls (  = 3). Ple se note that comp red to HEL cells MV4-11 cells have far less full-
length PARP1 and t at the lot of the anti-PARP1 antibody may h ve preferentially recognized the 
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treated with 10 nM or 30 nM LBH589 for 24 h. Thereafter, cells were washed twice with PBS and 
reseeded. Cells were stained with trypan blue and viable cells were counted after 4 days (n = 3; mean 
+ SD; one-way ANOVA; **** p ≤ 0.0001). 
2.2. Reduction of β-Catenin upon Class I HDAC Inhibition 
Since β-catenin is relevant for the growth and survival of leukemic cells [3–9], we tested whether 
LBH589 alte s the expression of this protei  i leukemic cells. Western blot analyses of MV4-11 and 
HEL cells reve led hat β-catenin as significantly degraded after incubation with LBH589. This led 
to the advent of an ad itional b n  that was rev le by th  β-cate in antibody (Figure 2A). The β-
catenin mRN  levels were not decreased by LBH589 (data not shown). 
s LBH589 blocks lass I, II, and IV H ACs [22], we addressed whether class I HDACs and/or 
HD C6 prevent the processi g of β-cat nin. We inhibited HDAC1-3 with MS-275 [22] and HDAC6 
with m rbo tat 100 [26]. W  noticed that MS-275 cause  the cleavage of PARP1 and β-catenin 
together with an a tivation of caspase-3 in bot  cell lines (Figure 2A). LBH589 and MS-275 also 
pr m ted an accumulation of   ɣ   H2AX ind catin  replicat on stress and/or DNA damage [21] in 
MV4 11 a d HEL cells (Fig re 2 ). We could confirm [26] that LBH589 attenuates the expression of 
HDAC6 n leukemic cell . M eover, LBH589 as well as marbostat-100 effectively inhibit HDAC6, 
which is eviden  as accumulation f acetylated tubulin [26,28,29]. Congruent with Figure 1A,B, 
marbosta -100 did not evoke the activa ion of caspase-3 or the processing of β-catenin (Figure 2A).  
To exclu e that the proc ssing of β-catenin in response to HDACi is an artifact of permanent 
l ukemic cell cu tures, we incub t d th  LTC FFM12 wi h BH589. As in permanent cell lines, 
LBH589 led to a cl avage of β-catenin and PARP1 (Figure 2B). 
Next, we compared the β-cate in levels of MV4-11 and HEL cells with the β-catenin levels in 
normal PBMCs. We included colo ctal cancer cells w h wild-type (RKO cells) or mutant β-catenin 
(HCT116 ells) for comparison. We found a similar expression of β-catenin in PBMCs, RKO, HEL, 
and MV4 11 cells. HCT116 cells showed the ex ected [56] verexpression of mutant β-catenin (Figure 
2C). These dat  sugg st tha  β-catenin is wild-type in MV4-11 and HEL cells. 
We noted the occurr nce of β-catenin cleavage pr ducts in c lls with a high activity of the 
a opto is exe uti ner enzyme caspase-3 (Figure 2A), which ca  cleave β-catenin [16,17]. Therefore, 
we spe lated that caspases process β-catenin in AML cells exposed to pro-apoptotic doses of 
LBH589. We tested this hypothesis with the pan-casp se inhibitor z-VAD-FMK. Incubation of AML 
cells wi h LBH589 and z-VAD-FMK prevented the occurrence of β-c tenin cleavage products and 
restored th  levels of full-length β-catenin (Figure 2D). We observed similar data for MS-275 and 
FK228 and the effici ncy of z-VAD-FMK was proven as abrogated activation of caspase-3 and intact 
PARP1 (Su plement ry Figure S3). 
To compl ment these analyses, we teste  for putative alter tions of the expression and 
phosphorylation dependent activation of GSK3β, which promotes the proteasomal degradation of β-
catenin [15]. We noted that HDACi do not alter tot l and ph sphorylated GSK3β in MV4-11 and 
FFM12 cell  (Fig re 2B, ). 
LBH589, MS-275, and FK228 increased t e levels of ɣH2AX and promoted apoptosis of MV4-11 
cells (Figure 2A, and Supplement ry Figure S3). DNA double strand breaks, which are generated 
upon DNA fragment tion by caspas -activated DNase, can also induce ɣH2AX [57,58]. Therefore, 
such an f ɣH2AX might be a consequence of apoptotic DNA fragmentation. To test 
th s, we i cubated MV4-11 cells with HDACi a d z-VAD-FMK. We found that this accumulation of 
ɣH2AX could only be partially abrogated with z-VAD-FMK (Supplementary Figure S3). These data 
agree with previous reports indicating that HDACs are gatekeepers of genomic integrity [21,28,59–
61]. 
H2AX
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could only be partially abrogated with z-VAD-FMK (Supplementary Figure S3). These data agree with
previous reports indicating that HDACs are gatekeepers of genomic integrity [21,28,59–61].
We summarize that LBH589 induced apoptosis concomitant with an attenuation of β-catenin.
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Figure 2. Caspases cleave β-catenin in leukemic cells. (A) MV4-11 and HEL cells were treated with 
increasing doses of marbostat-100 (M-100; 50 nM, 100 nM, 500 nM, and 1 µM), 5 µM of MS-275, or 30 
nM LBH589 for 24 h. Whole cell extracts were analyzed by Western blot as indicated (cl., cleaved; ac, 
acetylated), with β-actin as a loading control (n = 2). (B) Primary human FFM12 acute myeloid 
leukemia (AML) cells were incubated with 10 nM or 30 nM LBH589 for 24 h. Whole cell extracts were 
blotted for β-catenin, phosphorylated (p-) and total GSK3β, and PARP1; β-actin as loading control. 
(C) Indicated human cell lines and peripheral blood mononuclear cells (PBMCs) were compared 
regarding their β-catenin status. Whole cell extracts were analyzed by Western blot, with GAPDH 
and β-actin as loading controls (n = 2). (D) MV4-11 cells were pretreated with 20 µM or 50 µM of the 
pan-caspase inhibitor z-VAD-FMK for 1 h, followed by stimulation with 10 nM or 30 nM LBH589 for 
24 h. Whole cell extracts were blotted for the indicated proteins and β-actin as a loading control (n = 
2).2.3. Indomethacin Can Accentuate Anti-Proliferative Effects of LBH589. 
During the analysis of various AML cell lines, we noticed that the human myoblast cell line KG1 
was sensitive to apoptosis induction by LBH589, but retained β-catenin (Figure 3A–C). We observed 
a dose-dependent accumulation of acetylated histones and of acetylated tubulin in LBH589-treated 
KG1 cells (Figure 3A,B). This was associated with a dose-dependent cleavage of PARP1 (Figure 3A,C) 
and a significant increase in early and late apoptotic cells in KG1 cell cultures (Supplementary Figure 
i re . as ases cleave -catenin in leuke ic cells. (A) V4-11 and EL cells ere tr te it
i creasi ses f ar ostat-100 ( -100; 50 n , 100 n , 500 n , and 1 µ ), 5 f - , r 30
589 for 24 h. hole cell extracts were analyzed by Western blot as indicated (cl., cleaved; ac,
acet late ), ith β-actin as a loading control (n = 2). (B) Primary human FFM12 acute myeloid leukemia
(AML) cells were incubated with 10 nM or 30 n LBH589 for 24 h. Whole cell extracts were blotted for
β-catenin, phosphorylated (p-) and total GSK3β, and PARP1; β-actin as loading control. (C) Indicated
human cell lines and peripheral blood mononuclear cells (PBMCs) were compared regarding their
β-catenin status. Whole cell extracts were analyzed by Western blot, with GAPDH and β-actin as
loading controls (n = 2). (D) MV4-11 cells were pretreated with 20 µM or 50 µM of the pan-caspase
inhibitor z-VAD-FMK for 1 h, followed by stimulation with 10 nM or 30 nM LBH589 for 24 h. Whole
cell extracts were blotted for the indicated proteins and β-actin as a loading control (n = 2).
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a dose-dependent accumulation of acetylated histones and of acetylated tubulin in LBH589-treated
KG1 cells (Figure 3A,B). This was associated with a dose-dependent cleavage of PARP1 (Figure 3A,C)
and a significant increase in early and late apoptotic cells in KG1 cell cultures (Supplementary Figure
S4). Such an independence of apoptosis induction and β-catenin processing was also found in the
AML-LTC FFM05 (data not shown).
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Figure 3. Effects of LBH589 and indomethacin on β-catenin and cell proliferation. (A) KG1 cells were 
incubated with 10 nM, 30 nM, or 50 nM of LBH589 for 24 h. Indicated proteins were detected via 
Western blot (fl., full-length; cl., cleaved); with β-actin loading as control (n = 2). (B) KG1 and MV4-11 
cells were treated with LBH589 as indicated for 24 h. Western blot was performed for β-catenin, 
myelocytomatosis oncogene (MYC), acetylated (ac) tubulin, and β-actin as loading control (n = 2). (C) 
KG1 cells were incubated with 10–30 nM LBH589 ± 20–50 µM z-VAD-FMK for 24 h. Lysates of these 
cells were analyzed for β-catenin, full-length/cleaved PARP1 (fl./cl.), and MYC. A separate membrane 
was incubated with antibodies against total and phosphorylated (p) GSK3β; β-actin was used as 
loading control (n = 2). (D) KG1 cells were cultured in the presence or absence of 200 nM indomethacin 
for 24 h. Expression of β-catenin was assessed by Western blot; with β-actin as loading control (n = 2). 
(E) KG1 cells were treated with LBH589 and/or indomethacin as indicated. After 24 h of treatment, 
substances were washed out and cells were further cultured for proliferation analysis. After 4 days, 
proliferation was determined by trypan blue exclusion assay. Data are shown as mean values of cells 
per mL + SD (n = 3; one-way ANOVA; * p ≤ 0.05; ** p ≤ 0.01; **** p ≤ 0.0001). 
Differences in the HDACi-mediated regulation of β-catenin in MV4-11 cells and KG1 cells cannot 
be explained by differences in total and phosphorylated GSK3β, as these are unaltered by HDACi 
Figure 3. Effects of LBH589 and indomethacin on β-catenin a c ll li i . ( ) KG1 cells were
incubated with 10 nM, 30 nM, or 50 nM of LBH589 for 24 h. I i i s ere detected via
Western blot (fl., full-length; cl., cleaved); with β-actin loading as control (n ( ) KG1 and MV4- 1
cells were treated with LBH589 as indicated for 24 h. est f r ed for β-catenin,
myelocytomatosis oncogene (MYC), (ac) tubulin, and β-actin as loading control (n = 2).
(C) KG1 cells w re incubated with 1 –30 nM LBH589 ± 20–50 µM z-VAD-FMK for 24 h. Lysat s
of the e c lls were analyzed for β-cateni , full-length/cleaved PARP1 (fl./cl.), and MYC. A separate
membra e was incubated with antibodies against total and phosphorylated (p) GSK3β; β-actin was
used as loading control (n = 2). (D) KG1 cells were cultured in the presence or absence of 200 nM
indomethacin for 24 h. Expression of β-catenin was assessed by Western blot; with β-actin as loading
control (n = 2). (E) KG1 cells were treated with LBH589 and/or indomethacin as indicated. After 24 h
of treatment, substances were washed out and cells were further cultured for proliferation analysis.
After 4 days, proliferation was determined by trypan blue exclusion assay. Data are shown as mean
values of cells per mL + SD (n = 3; one-way ANOVA; * p ≤ 0.05; ** p ≤ 0.01; **** p ≤ 0.0001).
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Differences in the HDACi-mediated regulation of β-catenin in MV4-11 cells and KG1 cells cannot
be explained by differences in total and phosphorylated GSK3β, as these are unaltered by HDACi
(Figures 2D and 3C). Moreover, we could prove the efficacy of LBH589 in both MV4-11 and KG1 cells
as accumulation of acetylated forms of histone H3 and tubulin (Figure 3A,B).
A common response of primary and permanent cell lines to LBH589 is a reduction of MYC
(Figure 3B,C and Supplementary Figure S5) and this occurs irrespective of β-catenin in KG1 cells
(Figure 3B,C). Furthermore, in contrast to the caspase-dependent processing of β-catenin in MV4-11
cells (Figure 2D), the HDACi-mediated attenuation of MYC cannot be rescued by anti-apoptotic
concentrations of z-VAD-FMK in KG1 cells (Figure 3C).
The frequently prescribed NSAID indomethacin [62] has been reported to reduce β-catenin
expression in chronic myeloid leukemia (CML) cells [33]. We noted a detectable effect of indomethacin
against β-catenin in KG1 cells (Figure 3D). Therefore, we tested whether a reduction of β-catenin by
indomethacin combines favorably with LBH589 against KG1 cells. KG1 cells hardly recovered at low
density from a previous treatment with 30 nM LBH589 until day 4 after treatment discontinuation.
A near complete inhibition of proliferation until day 4 was caused by 50 nM LBH589. Indomethacin
dose-dependently suppressed the recovery of cells after drug removal and potentiated long-lasting
anti-proliferative effects of LBH589 at a low dose of 10 nM (Figure 3E).
These data suggest that indomethacin promotes LBH589-evoked anti-leukemic effects.
2.4. HDAC3 Activity Is Required to Maintain β-Catenin, MYC, and WT1
Specific HDACi are considered as agents that can eliminate cancer cells at a low cost of
side-effects [18–20]. Since HDAC3 is required for the survival and genomic integrity of leukemic
cells [59,60,63–65], we speculated that the pro-apoptotic and DNA-damaging effects of LBH589 and
MS-275 are due to an inhibition of HDAC3. To test this, we blocked HDAC3 with its specific inhibitor
RGFP966 [59,60,63,65,66]. We applied a maximal dose of 10 µM because RGFP966 does not inhibit any
other HDAC at a dose up to 15 µM in a biochemical assay [66]. Flow cytometry of fixed, propidium
iodide (PI)-stained cells MV4-11 cells revealed that treatment with RGFP966 for 24 h dose-dependently
triggered an increase of the subG1 fractions in AML cell cultures. 1, 5, and 10 µM RGFP966 increased
the subG1 fractions from 8% to 11%, 18%, and 25%, respectively. This effect was significant for
5–10 µM RGFP966 and it was associated with a significant reduction of cells in S phase and G2/M
phase (Figure 4A).
Pan-caspase inhibition with z-VAD-FMK prevented DNA fragmentation measured as subG1
fraction and the reduction of cells in G2/M phase by 10 µM RGFP966. Moreover, z-VAD-FMK
in combination with 5–10 µM RGFP966 increased the numbers of cells in G1 phase significantly.
The reduction of S phase cells by RGFP966 was though not affected by z-VAD-FMK (Figure 4A). These
findings suggest that RGFP966 causes apoptosis of MV4-11 cells and that this prevents an accumulation
of cells in the G1 and G2/M phases in response to RGFP966.
Annexin-V staining verified that 1, 5, and 10 µM RGFP966 increase apoptosis from 4.6% to 5.4%,
16%, and 25%, respectively in MV4-11 cell cultures. This experiment also shows that 5–10 µM RGFP966
evoke a significant increase in cells in late apoptosis (Figure 4B; see Supplementary Figure S6 for
exemplary dot blots). This notion is consistent with the typical occurrence of fragmented DNA during
the late apoptotic process (Figure 4A). Consistent herewith, we observed an apoptotic cleavage of
caspase-3 and PARP1 (Figure 4C).
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 Figure 4. Biological consequences of HDAC3 inhibition and interplay between β-catenin, MYC, and
WT1. (A) MV4-11 cells were pretreated with z-VAD-FMK for 1 h, followed by incubation with RGFP966
as indicated for 24 h. Cells were fixed and stained with PI and analyzed by flow cytometry (n = 3;
mean + SD; two-way ANOVA; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001). (B) MV4-11 cells were treated as
indicated for 24 h. After incubation time, cells were stained with annexin-V-FITC/PI and apoptosis was
determined by flow cytometry (n = 3; mean + SD; two-way ANOVA; ** p ≤ 0.01). (C) MV4-11 cells
were treated with increasing doses of RGFP966 (1 µM, 5 µM, and 10 µM) for 24 h. Caspase-3, PARP1,
and WT1 (→marks WT1 cleavage product) were analyzed by Western blot, with vinculin as loading
control (n = 2). (D) MV4-11 cells were treated as stated in (C). Indicated proteins were detected via
Western blot, with GAPDH as loading control (n = 2). (E) Immunofluorescence for 53BP1 in MV4-11
cells that remained untreated or exposed to 1 µM RGFP966 for 24 h. (F) MV4-11 cells were treated as
indicated for 24 h. Thereafter, cells were harvested and washed with PBS and reseeded. After 4 days,
the cell numbers were determined by trypan blue staining and counting (n = 3; mean + SD; one-way
ANOVA; ** p ≤ 0.01; *** p ≤ 0.001).
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It is often unknown if the inhibition of one single HDAC is sufficient to attenuate oncogenic proteins.
Therefore, we tested for a potential impact of RGFP966 on the leukemia- and stemness-associated
transcription factors β-catenin, MYC, and WT1. We found that RGFP966 reduced WT1 and led
to the advent of a WT1 cleavage product (Figure 4C), which is seen in leukemic cells undergoing
apoptosis [29,55]. A loss of WT1 has consistently been noted in K562 cells treated with FK228 [29].
RGFP966 also attenuated the expression of β-catenin and MYC in a dose-dependent manner and led to
the occurrence of a β-catenin cleavage product (Figure 4D).
As expected [59,60,63], RGFP966 also caused an accumulation of
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as loading controls (n = 3). Please note that compared to HEL cells MV4-11 cells have far less full-
length PARP1 and that the lot of the anti-PARP1 antibody may have preferentially recognized the 
cleaved form of PARP1. (D) Regrowth of the human leukemia cell lines MV4-11 and HEL. Cells were 
treated with 10 nM or 30 nM LBH589 for 24 h. Thereafter, cells were washed twice with PBS and 
reseeded. Cells were stained with trypan blue and viable cells were counted after 4 days (n = 3; mean 
+ SD; one-way ANOVA; **** p ≤ 0.0001). 
2.2. Reduction of β-Catenin upon Class I HDAC Inhibition 
Since β-catenin is relevant for the growth and survival of leukemic cells [3–9], we tested whether 
LBH589 alters the expression of this protein in leukemic cells. Western blot analyses of MV4-11 and 
HEL cells revealed that β-catenin was significantly degraded after incubation with LBH589. This led 
to the advent of an additional band that was revealed by the β-catenin antibody (Figure 2A). The β-
catenin mRNA levels were not decreased by LBH589 (data not shown). 
As LBH589 blocks class I, II, and IV HDACs [22], we addressed whether class I HDACs and/or 
HDAC6 prevent the processing of β-catenin. We inhibited HDAC1-3 with MS-275 [22] and HDAC6 
with marbostat-100 [26]. We noticed that MS-275 caused the cleavage of PARP1 and β-catenin 
together with an activation of caspase-3 in both cell lines (Figure 2A). LBH589 and MS-275 also 
promoted an accumulation of   ɣ   H2AX indicating replication stress and/or DNA damage [21] in 
MV4-11 and HEL cells (Figure 2A). We could confirm [26] that LBH589 attenuates the expression of 
HDAC6 in leukemic cells. Moreover, LBH589 as well as marbostat-100 effectively inhibit HDAC6, 
which is evident as accumulation of acetylated tubulin [26,28,29]. Congruent with Figure 1A,B, 
marbostat-100 did not evoke the activation of caspase-3 or the processing of β-catenin (Figure 2A).  
To exclude that the processing of β-catenin in response to HDACi is an artifact of permanent 
leukemic cell cultures, we incubated the LTC FFM12 with LBH589. As in permanent cell lines, 
LBH589 led to a cleavage of β-catenin and PARP1 (Figure 2B). 
Next, we compared the β-catenin levels of MV4-11 and HEL cells with the β-catenin levels in 
normal PBMCs. We included colorectal cancer cells with wild-type (RKO cells) or mutant β-catenin 
(HCT116 cells) for comparison. We found a similar expression of β-catenin in PBMCs, RKO, HEL, 
and MV4-11 cells. HCT116 cells showed the expected [56] overexpression of mutant β-catenin (Figure 
2C). These data suggest that β-catenin is wild-type in MV4-11 and HEL cells. 
We noted the occurrence of β-catenin cleavage products in cells with a high activity of the 
apoptosis executioner enzyme caspase-3 (Figure 2A), which can cleave β-catenin [16,17]. Therefore, 
we speculated that caspases process β-catenin in AML cells exposed to pro-apoptotic doses of 
LBH589. We tested this hypothesis with the pan-caspase inhibitor z-VAD-FMK. Incubation of AML 
cells with LBH589 and z-VAD-FMK prevented the occurrence of β-catenin cleavage products and 
restored the levels of full-length β-catenin (Figure 2D). We observed similar data for MS-275 and 
FK228 and the efficiency of z-VAD-FMK was proven as abrogated activation of caspase-3 and intact 
PARP1 (Supplementary Figure S3). 
To complement these analyses, we tested for putative alterations of the expression and 
phosphorylation-dependent activation of GSK3β, which promotes the proteasomal degradation of β-
catenin [15]. We noted that HDACi do not alter total and phosphorylated GSK3β in MV4-11 and 
FFM12 cells (Figure 2B,D). 
LBH589, MS-275, and FK228 increased the levels of ɣH2AX and promoted apoptosis of MV4-11 
cells (Figure 2A, and Supplementary Figure S3). DNA double strand breaks, which are generated 
upon DNA fragmentation by caspase-activated DNase, can also induce ɣH2AX [57,58]. Therefore, 
such an accumulation of ɣH2AX might be a consequence of apoptotic DNA fragmentation. To test 
this, we incubated MV4-11 cells with HDACi and z-VAD-FMK. We found that this accumulation of 
ɣH2AX could only be partially abrogated with z-VAD-FMK (Supplementary Figure S3). These data 
agree with previous reports indicating that HDACs are gatekeepers of genomic integrity [21,28,59–
61]. 
H2AX indicating replication
stress and DNA damage (Figure 4D). To assess if this increase in
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as loading controls (  = 3). Please n te that compared to HEL cells MV4-11 c lls have far less full-
length PARP1 and that the lot of the anti-PARP1 antibody may have preferentially recognized the 
cleaved form of PARP1. (D) Regrowth of the human leuk mia cell lines MV4-11 and HEL. Cells were 
treated with 10 nM or 30 nM LBH589 for 24 h. Thereafter, cells were washed twice with PBS and 
reseeded. Cells ere stained with trypan blue and viable cells were counted after 4 days (n = 3; mean 
+ SD; one-way ANOVA; **** p ≤ 0.0001). 
2.2. Reduction of β-Catenin upon Class I HDAC Inhibition 
Since β-ca nin is r levant for the growth a d survival of leukemic c lls [3–9], we tested whether
LBH589 alter the expression of his protein i  leukemic cells. Western blot analyses of MV4-11 and 
HEL cells revealed that β-catenin was significantly degra ed aft r incubation with LBH589. This led 
to the advent of an additional band that was revealed by the β-catenin antibody (Figure 2A). The β-
catenin mRNA levels were not decreased by LBH589 (data not shown). 
As LBH589 blocks class I, II, and IV HDACs [22], we addressed whether class I HDACs and/or 
HDAC6 prevent the processing of β-cat nin. We inhibited HDAC1-3 with MS-275 [22] and HDAC6 
with marbostat-100 [26]. We noticed that MS-275 caused the cleavage of PARP1 and β-catenin 
together with tivation f caspase-3 in both cell l es (Figure 2A). LBH589 and MS-275 also 
promoted an accumulation of   ɣ   H2AX indicating replication stress and/or DNA damage [21] in 
MV4-11 and HEL cells (Figure 2A). We could confirm [26] that LBH589 attenuates th  expression of 
HDAC6 in leukemic cells. Moreover, LBH589 as well as marbostat-100 effectively inhibit HDAC6, 
which is evident as accumulation of acetylated tubulin [26,28,29]. Congruent with Figure 1A,B, 
marbostat-100 did no  evoke the activation of spase-3 or the processing of β-catenin (Figure 2A).  
To exclude that the process g of β-ca enin in response to HDACi is an artifact of p rmanent 
leukemic cel  cultures, we incubated the LTC FFM 2 with L H589. As in permanent cell lines, 
LBH589 led to a cleavage of β-catenin and PARP1 (Figure 2B). 
Next, we compared the β-catenin leve s of MV4-11 and HEL cells with th  β-catenin levels in 
normal PBMCs. We included col rectal cancer cells with wild-type (RKO cells) or mutant β-catenin 
(HCT116 cells) for comparison. We found a similar expression of β-catenin in PBMCs, RKO, HEL, 
and MV4-11 c lls. HCT116 cells showed the expected [56] overexpression of mutant β-catenin (Figure 
2C). These data suggest that β-catenin is wild-type in MV4-11 and HEL . 
We n ted the occur ence of β-catenin cleavage products in cells with a high activity of th  
apoptosi  execu ioner enzyme ca pase-3 (Figure 2A), which can c eave β-catenin [16,17]. Therefore, 
we speculated that caspases pr ces  β-catenin in AML cells exposed to pro-apoptotic doses of 
LBH589. We tested this hypothesis with the pan-caspase inhibitor z-VAD-FMK. Incub tion of AML
cells with LBH589 and z-VAD-FMK prevented the occurrence of β-catenin cleavage products and
restored the levels o  full-length β-catenin (Figure 2D). We observe  simil r data for MS-275 and 
FK228 and the efficiency of z-VAD-FMK was proven as abrogated activation of caspase-3 and intact 
PARP1 (Supple entary Figure S3). 
To complement these analyses, we tested for putative alterations f the expr ssion and 
phosphorylation-depend nt activation of GSK3β, which promotes the pr teasomal degradation of β-
catenin [ 5]. We noted that HDACi do not alter total and phosphorylated GSK3β in MV4-11 and 
FFM12 cells (Figure 2B,D).
LBH589, MS- 75, and FK228 incre sed the l vels of ɣH2AX and p omoted apoptosis of MV4-11 
cells (Figure 2 , and Supplementary Figure S3). DNA double strand breaks, which are generated 
upon DNA fragment by caspase-activated DNas , ca  also induce ɣH2AX [57,58]. Therefore, 
such an accumulation of ɣH2AX might be a consequence of apoptotic DNA fragmentation. To test 
this, we incubate  MV4-11 cells with HDACi and z-VAD-FMK. We found that this accumulation of 
ɣH2AX could only be partially abrogated with z-VAD-FMK (Suppl mentary Figure S3). These data 
agree with previous reports indicating that HDACs are gatekeepers of genomic integrity [21,28,59–
61]. 
H2 X is linked to DNA damage
or a consequence of DNA fragmentation by apoptosis [57,58], we incubated MV4-11 cells with 1 µM
RGFP966. We chose this dose as it does not evoke significant DNA fragmentation (Figure 4A) and
stained cells for 53BP1 foci by immunofluorescence. We chose this marker by virtue of its ability to
stain DNA breaks within foci [67]. We could readily detect 53BP1 foci formation associated with 53BP1
nuclear translocation in RGFP966-treated MV4-11 cells (Figure 4E), indicating DNA damage.
Due to the accumulation of
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0.01; *** p ≤ 0.001; **** p ≤ 0.0001). (C) Cells were treated with 10 nM or 30 nM LBH589 for 24 h. 
Indicated proteins were detected via Western blot (cl., cleaved; fl., full-length) with HSP90 and β-actin 
as loading controls (n = 3). Please note that compared to HEL cells MV4-11 cells have far less full-
length PARP1 and that the lot of the anti-PARP1 antibody may have preferentially recognized the 
cleaved form of PARP1. (D) Regrowth of the human leukemia cell lines MV4-11 and HEL. Cells were 
treated with 10 nM or 30 nM LBH589 for 24 h. Thereafter, cells were washed twice with PBS and 
reseeded. Cells were stained with trypan blue and viable cells were counted after 4 days (n = 3; mean 
+ SD; one-way ANOVA; **** p ≤ 0.0001). 
2.2. Reduction of β-Catenin upon Class I HDAC Inhibition 
Since β-catenin is relevant for the growth nd survival of leukemic ells [3–9], we tested whether 
LBH589 alters the expression of this pr tein in leukemic cells. Western blot analyses f MV4-11 and 
HEL cells revealed that β-catenin was significantly degraded after incubation with LBH589. This led 
to the advent of an additional band that was revealed by the β-catenin antibody (Figure 2A). The β-
catenin mRNA levels were not decreased by LBH589 (data not shown). 
As LBH589 blocks class I, II, and IV HDACs [22], w  addressed whether class I HDACs a d/or 
HDAC6 prevent the processing of β-catenin. We inhib ted HDAC1-3 with MS-275 [22] and HDAC6 
with marbostat-100 [26]. We noticed that MS-275 caused the cleavage of PARP1 and β-catenin 
together with an activation of caspase-3 in both cell lin s (Figure 2A). LBH589 a d MS-275 also 
promoted an accumulation of   ɣ   H2AX indi ating replic t on stress and/or DN  damage [21] in 
MV4-11 and HEL cells (Figure 2A). We coul  c nfirm [26] that LBH589 tte uates the expression of 
HDAC6 in leukemic cells. Moreover, LBH589 as well as marbost t-100 effectively inhibit HDAC6, 
which is evident as accumulatio  of cetylated tubulin [26,28,29]. Congrue t with F gure 1A,B, 
marbostat-100 did not evoke the activation of caspas -3 or the proces ing of β-catenin (Figure 2A).  
To exclude that the processing of β-catenin in re ponse to HDACi is an artifact of permanent
leukemic cell cultures, we incubated t  LTC FFM12 with LBH589. A  in permanent cell lines,
LBH589 led to a cleavage of β-catenin nd PARP1 (Figure 2B). 
Next, we compared the β-catenin l vels of MV4-11 and HEL cell  with the β-catenin levels in 
normal PBMCs. We included colorectal cancer cells with wild-t e (RKO cells) or mutant β- ate in 
(HCT116 cells) for comparison. We found a similar expression of β-catenin in PBMCs, RKO, HEL,
and MV4-11 cells. HCT116 cells showed the expect d [56] overexpression of mu a t β-catenin (Figure
2C). These data suggest that β-catenin is wild-type in MV4-11 and HEL c lls. 
We noted the occurrence of β-catenin cleavage products n c lls with a high activity of he 
apoptosis executioner enzyme caspase-3 (Figure 2A), which can cle ve β-catenin [16,17]. Therefore, 
we speculated that caspases process β-catenin in AML c lls exposed t  pro-apoptotic doses of 
LBH589. We tested this hypothesis with he p n-caspase inhibitor z-VAD-FM . Incubati n f AML 
cells with LBH589 and z-VAD-FMK prevented the ccurrence of β-cateni  cleavage products and 
restored the levels of full-length β-catenin (Figure 2D). We observed s milar data for MS-275 and 
FK228 and the efficiency of z-VAD-FMK was proven as brogated activation of caspase-3 and intact 
PARP1 (Supplementary Figure S3). 
To complement these analyses, we tested for putative alter tions of the expression and 
phosphorylation-dependent activation of GSK3β, wh ch promotes the pro easomal degradati n of β-
catenin [15]. We noted that HDACi do not alter total and phosphorylated GSK3β in MV4-11 and 
FFM12 cells (Figure 2B,D). 
LBH589, MS-275, and FK228 increased the levels of ɣH2AX and promoted apoptosis of MV4-11 
cells (Figure 2A, and Supplementary Figure S3). DNA double strand breaks, which are generated 
upon DNA fragmentation by caspase-activated DNase, can also induce ɣH2AX [57,58]. Therefore, 
such an accumulation of ɣH2AX might be a consequence of apoptotic DNA fragmentation. To test 
this, we incubated MV4-11 cells with HDACi and z-VAD-FMK. We found that this accumulation of 
ɣH2AX could only be partially abrogated with z-VAD-FMK (Supplementary Figure S3). These data 
agree with previous reports indicating that HDACs are gatekeepers of genomic integrity [21,28,59–
61]. 
H2AX and 53BP1 foci in response to HDACi (Figure 2A, Figure 4D,E,
and Supplementary Figure S3), we asked whether the reduced stability of β-catenin, MYC, and WT1
could also occur upon replication stress/DNA damage. Therefore, we assessed a putative regulation of
these proteins by hydroxyurea (HU). We chose this clinically widely used drug, because it is a bona fide
inducer of replication stress and DNA damage. Moreover, HU leads to a caspase-dependent processing
of WT1 in leukemic cells [29,55]. HU dose-dependently reduced full-length β-catenin and led to the
appearance of cleaved β-catenin. Furthermore, HU reduced MYC and caused an accumulation of
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Indicated proteins were detected via Western blot (cl., cleaved; fl., full-length) with HSP90 and β-actin 
as loading controls (n = 3). Please note that compared to HEL cells MV4-11 cells have far less full-
length PARP1 and that the lot of the anti-PARP1 antibody may have preferentially recognized the 
cleaved form of PARP1. (D) Regrowth of the human leukemia cell lines MV4-11 and HEL. Cells were 
treated with 10 nM or 30 nM LBH589 for 24 h. Thereafter, cells were washed twice with PBS and 
reseeded. Cells were stained with trypan blue and viable cells were counted after 4 days (n = 3; mean 
+ SD; one-way ANOVA; **** p ≤ 0.0001). 
2.2. Reduction of β-Catenin upon Class I HDAC Inhibition 
Since β-catenin is relevant for e growth nd survival of leukemic cells [3–9], we test  w eth r 
LBH589 alters the expression of this protein in leukemic cells. We tern blot analyses of MV4-11 and 
HEL cells revealed that β-catenin was signific ntly degraded after incubation with LBH589. This led 
to the advent of an additional band that was reveal d by the β-catenin antibody (Figure 2A). The β-
catenin mRNA levels were not decreased by LBH589 (data not shown). 
As LBH589 blocks class I, II, and IV HDACs [22], we addressed whether class I HDACs and/or 
HDAC6 prevent the processing of β-ca enin. We inhibited HDAC1-3 with S-275 [22] and HDAC6 
with marbostat-100 [26]. We noticed that MS-275 caused the cleavage of PARP1 and β- atenin 
together with an activation of caspase-3 in both cell lin s (Figure 2A). LBH589 and MS-275 also 
promoted an accumulation of   ɣ   H2AX indi ating r plication stress and/or DNA damag  [21] in 
MV4-11 and HEL cells (Figure 2A). W  could confirm [26] that LBH589 attenuates the expres ion of 
HDAC6 in leukemic cells. Moreover, LBH589 as well as marb stat-100 effec iv y inhibit HDAC6, 
which is evident as accumulation of acety ated tubulin [26,28,29]. Congru nt with Figure 1A,B, 
marbostat-100 did not evoke the activation of ca pase-3 or the pro ssing f β-cat nin (Figure 2A).  
To exclude that the processing of β-catenin in response to HDACi is an artifact of p rmanent 
leukemic cell cultures, we incubated the LTC FFM12 with LBH589. s in permanent cell lines, 
LBH589 led to a cleavage of β-catenin and PARP1 (Figure 2B). 
Next, we compared the β-catenin levels of MV4-11 nd HEL cells wi h the β-catenin l vels in 
normal PBMCs. We included colorectal cancer c lls wit  wild-type (RKO cells) r muta t β-ca enin 
(HCT116 cells) for comparison. We found a similar expression of β-cat ni  in PBMCs, RKO, EL, 
and MV4-11 cells. HCT116 cells showed the expected [56] overexpression of mutant β-catenin (Figure 
2C). These data suggest that β-catenin is wild-type n MV4-11 and HEL cells. 
We noted the occurrence of β-catenin cl avage prod cts in cells with a high activi y f the
apoptosis executioner enzyme caspase-3 (Figure 2A), which can cleave β-catenin [16,17]. Ther fore, 
we speculated that caspases process β-cateni  in AML cells exp sed to pro-apoptotic doses of 
LBH589. We tested this hypothesis with the pan-caspase inhibitor z-VAD-FMK. Incubation of AML 
cells with LBH589 and z-VAD- MK prevented th  occurrence of β-c tenin cleavage products and 
restored the levels of full-length β-catenin (Figure 2D). We observed similar data for MS-275 
FK228 and the efficiency of z-VAD-FMK was proven as abrogated activation of caspase-3 and intact 
PARP1 (Supplementary Figure S3). 
To complement these analyses, we tested f r putative alterations of th  expr ssion and 
phosphorylation-dependent activation of GSK3β, which promotes the proteasomal degradation of β-
catenin [15]. We noted that HDACi do not alter total nd phosphorylated GSK3β in MV4-11 and 
FFM12 cells (Figure 2B,D). 
LBH589, MS-275, and FK228 increased the levels of ɣH2AX and promoted apoptosis of MV4-11 
cells (Figure 2A, and Supplementary Figure S3). DNA double strand breaks, which are generated 
upon DNA fragmentation by caspase-activated DNase, can also induce ɣH2AX [57,58]. Therefore, 
such an accumulation of ɣH2AX might be a consequence of apoptotic DNA fragmentation. To test 
this, we incubated MV4-11 cells with HDACi and z-VAD-FMK. We found that this accumulation of 
ɣH2AX could only be partially abrogated with z-VAD-FMK (Supplementary Figure S3). These data 
agree with previous reports indicating that HDACs are gatekeepers of genomic integrity [21,28,59–
61]. 
2AX without altering the acetylation levels of histone H3 (Supplementary Figure S7).
A loss of proliferation-associated transcription factors as well as replication stress/DNA damage
can cause a permanent growth arrest [13,21]. Assessment of regrowth capacities showed that RGFP966
doses that significantly evoked apoptosis also restrained proliferation after drug removal. Moreover,
5 µ RGFP966 were about as effective as 30 nM LBH589 (Figure 4F).
These data suggest that HDAC3 is necessary for AML cell survival and the maintenance of
β-catenin, MYC, WT1, and the prevention of replication stress and DNA damage.
2.5. I terplay between β-C t nin, MYC, and WT1
Since there is ample evidence for an interaction of β-catenin, MYC, and WT1 at multiple levels
(e.g., [13,23,37–40,45,68]), we tested with RNAi whether these factors regulate each other in MV4-11 cells.
On the one hand, a reduction of MYC led to a reduction of WT1, indicating that MYC promotes the
expression of WT1. On the other hand, a reduction of WT1 increased the levels of MYC (Figure 5A,B).
Furthermore, a reduction of WT1 increased the levels of β-catenin, signifying that WT1 negatively
regulates both β-catenin and MYC. A knockdown of β-catenin produced no effects on MYC and WT1
(Figure 5A,B). Flow cytometry assessing PI showed that the reduction of these three proteins up to 48 h
did not affect the vitality of MV4-11 cells (Figure 5B). Hence, the interplay between MYC and WT1 is
not a consequence of cell death.
These data illustrate that MYC and WT1 regulate each other and that WT1 reduces β-catenin
levels in MV4-11 cells.
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si, siRNA). Proteins were detected by Western blot, with HSP90 as loading control (n = 3). (B) 
Densitometry evaluation of data shown in (A) (n = 3; mean + SD; two-way ANOVA; * p ≤ 0.05; *** p ≤ 
0.001; **** p ≤ 0.0001). (C) Flow cytometry was done with aliquots of MV4-11 cells with an efficient 
elimination of β-catenin, MYC, or WT1. Cells were fixed, PI-stained, and assessed for apoptotic DNA 
fragmentation (n = 3; two-way ANOVA; not significant). 
3. Discussion 
We showed that LBH589 evoked growth arrest and apoptosis in leukemic cells. As this effect 
was also seen with MS-275, FK228 and RGFP966, we concluded that class I HDACs, and particularly 
HDAC3, were necessary for the survival of leukemic cells. The compromised survival of HDACi-
exposed leukemic cells is associated with an accumulation of the replication stress/DNA damage 
marker ɣH2AX and with the formation of 53BP1 foci. 1 µM RGFP966 evokes replication stress/DNA 
damage without massive apoptotic DNA damage and z-VAD-FMK cannot abrogate ɣH2AX 
accumulation in HDACi-treated leukemic cells. From these data we deduced that HDACi-induced 
replication stress/DNA damage precedes apoptotic DNA fragmentation, which can also trigger the 
formation of ɣH2AX [57,58]. Others also report that a pharmacological interference with HDAC3 
triggers replication stress, DNA damage, cell death, and enhanced chemosensitivity of lymphocytic 
and myeloid leukemia cells [59,60,63,65,69]. Such data are consistent with the reported impaired 
DNA repair capacities of HDACi-treated leukemic cells [21,28,59–61,63,64,70]. 
Figure 5. Cross-talk between β-catenin, MYC, and WT1. (A) MV4-11 cells were electroporated
with 100 pmol of indicated siRNAs and incubated for 48 h (NC siRNA, scrambled irrelevant control
siRNA; si, siRNA). Proteins were detected by Western blot, with HSP90 as loading control (n = 3).
(B) Densitometry evaluation of data shown in (A) (n = 3; mean + SD; two-way ANOVA; * p ≤ 0.05;
*** p ≤ 0.001; **** p ≤ 0.0001). (C) Flow cytometry was done with aliquots of MV4-11 cells with an
efficient elimination of β-catenin, MYC, or WT1. Cells were fixed, PI-stained, and assessed for apoptotic
DNA fragmentation (n = 3; two-way ANOVA; not significant).
3. Discussion
We showed that LBH589 evoked growth arrest and apoptosis in leukemic cells. As this effect was
also seen with MS-275, FK228 and RGFP966, we concluded that class I HDACs, and particularly HDAC3,
were necessary for the survival of leukemic cells. The compromised survival of HDACi-exposed
leukemic cells is associated with an accumulation of the replication stress/DNA damage marker
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0.01; *** p ≤ 0.001; **** p ≤ 0.0001). (C) Cells were treated with 10 nM or 30 nM LBH589 for 24 h. 
Indicated proteins were detected via Western blot (cl., cleaved; fl., full-length) with HSP90 and β-actin 
as loading controls (n = 3). Please note that compared to HEL cells MV4-11 cells have far less full-
length PARP1 and that the lot of the anti-PARP1 antibody may have preferentially recognized the 
cleaved form of PARP1. (D) Regrowth of the human leukemia cell lines MV4-11 and HEL. Cells were 
treated with 10 nM or 30 nM LBH589 for 24 h. Thereafter, cells were washed twice with PBS and 
reseeded. Cells were stained with trypan blue and viable cells were counted after 4 days (n = 3; mean 
+ SD; one-way ANOVA; **** p ≤ 0.0001). 
2.2. Reduction of β-Catenin upon Class I HDAC Inhibition 
Since β-catenin is relevant for the growth and survival of leukemic cells [3–9], we tested whether 
LBH589 alters the expression of this protein in leukemic cells. Western blot analyses of MV4-11 and 
HEL cells revealed that β-catenin was significantly degraded after incubation with LBH589. This led 
to the advent of an additional band that was revealed by the β-catenin antibody (Figure 2A). The β-
catenin mRNA levels were not decreased by LBH589 (data not shown). 
As LBH589 blocks class I, II, and IV HDACs [22], we addressed whether class I HDACs and/or 
HDAC6 prevent the processing of β-catenin. We inhibited HDAC1-3 with MS-275 [22] and HDAC6 
with marbostat-100 [26]. We noticed that MS-275 caused the cleavage of PARP1 and β-catenin 
together with an activation of caspase-3 in both cell lines (Figure 2A). LBH589 and MS-275 also 
promoted an accumulation of   ɣ   H2AX indicating replication stress and/or DNA damage [21] in 
MV4-11 and HEL cells (Figure 2A). We could confirm [26] that LBH589 attenuates the expression of 
HDAC6 in leukemic cells. Moreover, LBH589 as well as marbostat-100 effectively inhibit HDAC6, 
which is evident as accumulation of acetylated tubulin [26,28,29]. Congruent with Figure 1A,B, 
marbostat-100 did not evoke the activation of caspase-3 or the processing of β-catenin (Figure 2A).  
To exclude that the processing of β-catenin in response to HDACi is an artifact of permanent 
leukemic cell cultures, we incubated the LTC FFM12 with LBH589. As in permanent cell lines, 
LBH589 led to a cleavage of β-catenin and PARP1 (Figure 2B). 
Next, we compared the β-catenin levels of MV4-11 and HEL cells with the β-catenin levels in 
normal PBMCs. We included colorectal cancer cells with wild-type (RKO cells) or mutant β-catenin 
(HCT116 cells) for comparison. We found a similar expression of β-catenin in PBMCs, RKO, HEL, 
and MV4-11 cells. HCT116 cells showed the expected [56] overexpression of mutant β-catenin (Figure 
2C). These data suggest that β-catenin is wild-type in MV4-11 and HEL cells. 
We noted the occurrence of β-catenin cleavage products in cells with a high activity of the 
apoptosis executioner enzyme caspase-3 (Figure 2A), which can cleave β-catenin [16,17]. Therefore, 
we speculated that caspases process β-catenin in AML cells exposed to pro-apoptotic doses of 
LBH589. We tested this hypothesis with the pan-caspase inhibitor z-VAD-FMK. Incubation of AML 
cells with LBH589 and z-VAD-FMK prevented the occurrence of β-catenin cleavage products and 
restored the levels of full-length β-catenin (Figure 2D). We observed similar data for MS-275 and 
FK228 and the efficiency of z-VAD-FMK was proven as abrogated activation of caspase-3 and intact 
PARP1 (Supplementary Figure S3). 
To complement these analyses, we tested for putative alterations of the expression and 
phosphorylation-dependent activation of GSK3β, which promotes the proteasomal degradation of β-
catenin [15]. We noted that HDACi do not alter total and phosphorylated GSK3β in MV4-11 and 
FFM12 cells (Figure 2B,D). 
LBH589, MS-275, and FK228 increased the levels of ɣH2AX and promoted apoptosis of MV4-11 
cells (Figure 2A, and Supplementary Figure S3). DNA double strand breaks, which are generated 
upon DNA fragmentation by caspase-activated DNase, can also induce ɣH2AX [57,58]. Therefore, 
such an accumulation of ɣH2AX might be a consequence of apoptotic DNA fragmentation. To test 
this, we incubated MV4-11 cells with HDACi and z-VAD-FMK. We found that this accumulation of 
ɣH2AX could only be partially abrogated with z-VAD-FMK (Supplementary Figure S3). These data 
agree with previous reports indicating that HDACs are gatekeepers of genomic integrity [21,28,59–
61]. 
H2AX and with the formation of 53BP1 foci. 1 µM RGFP966 evokes replication stress/DNA damage
without massive apoptotic DNA damage and z-VAD-FMK cannot abrogate
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2.2. Reduction of β-Catenin upon Class I HDAC Inhibition 
Since β-catenin is relevant for the growth and survival of leukemic cells [3–9], we tested whether 
LBH589 alters t e expression of this protein in leukemic cells. Western blot analyses of MV4-11 and 
HEL cells revealed that β-catenin was significantly degraded after incubation with LBH589. This led 
to the advent of an additional band that was revealed by the β-catenin antibody (Figure 2A). The β-
atenin mRNA levels were not decreased by LBH589 (data not shown). 
As LBH589 blocks class I, II, and IV HDACs [22], we addressed whether class I HDACs and/or 
HDAC6 prevent he processing of β-catenin. We inhibited HDAC1-3 with MS-275 [22] and HDAC6 
with arbostat-100 [26]. We noticed that MS-275 caused the cleavage of PARP1 and β-catenin 
together with an activation of caspase-3 in both cell lines (Figure 2A). LBH589 and MS-275 also 
promot d an accumulation of   ɣ   H2AX indicating replication stress and/or DNA damage [21] in 
MV4-11 and EL cells (Figure 2A). We could confirm [26] that LBH589 attenuates the expression of 
HDAC6 in leukemic cells. Moreover, LBH589 as well as marbostat-100 effectively inhibit HDAC6, 
which is evid nt as accumulation of acetylated tubulin [26,28,29]. Congruent with Figure 1A,B, 
marbostat-100 did no evoke the activation of caspase-3 or the processing of β-catenin (Figure 2A).  
To xclude that the processing of β-catenin in response to HDACi is an artifact of permanent 
leukemic cell cultures, we incubated the LTC FFM12 with LBH589. As in permanent cell lines, 
LBH589 led to a cleavage of β-catenin and PARP1 (Figure 2B). 
Next, we ompared the β-catenin levels of MV4-11 and HEL cells with the β-catenin levels in 
ormal PBMCs. We included colorectal cancer cells with wild-type (RKO cells) or mutant β-catenin 
(HCT116 cells) for comparison. We found a similar expression of β-catenin in PBMCs, RKO, HEL, 
and MV4-11 cells. HCT116 cells showed the expected [56] overexpression of mutant β-catenin (Figure 
2C). These data sugg st that β-catenin is wild-type in MV4-11 and HEL cells. 
We noted the occurrence of β-catenin cleavage products in cells with a high activity of the 
apo tosis executioner enzyme caspase-3 (Figure 2A), which can cleave β-catenin [16,17]. Therefore, 
we speculated that caspases process β-catenin in AML cells exposed to pro-apoptotic doses of 
LBH589. We tes ed this hypothesis with the pan-caspase inhibitor z-VAD-FMK. Incubation of AML 
cells with LBH589 and z-VAD-FMK prevented the occurrence of β-catenin cleavage products and 
restored the levels of full-length β-catenin (Figure 2D). We observed similar data for MS-275 and 
FK228 and the efficiency of z-VAD-FMK was proven as abrogated activation of caspase-3 and intact 
PARP1 (Supplementary Figure S3). 
To complement these analyses, we tested for putative alterations of the expression and 
phosphorylation-dependent activation of GSK3β, which promotes the proteasomal degradation of β-
catenin [15]. We noted that HDACi do not alter total and phosphorylated GSK3β in MV4-11 and 
FFM12 cells (Figure 2B,D). 
LBH589, MS-275, and FK228 increased the levels of ɣH2AX and promoted apoptosis of MV4-11 
cells (Figure 2A, and Supplementary Figure S3). DNA double strand breaks, which are generated 
upon DNA fragmentation by caspase-activated DNase, can also induce ɣH2AX [57,58]. Therefore, 
such an accumulation of ɣH2AX might be a consequence of apoptotic DNA fragmentation. To test 
this, we incubat d MV4-11 cells with HDACi and z-VAD-FMK. We found that this accumulation of 
ɣH2AX could only be partially abrogated with z-VAD-FMK (Supplementary Figure S3). These data 
agree with previous reports indicating that HDACs are gatekeepers of genomic integrity [21,28,59–
61]. 
H2AX accumulation
in HDACi-treated leuke ic cells. From these data we deduced that HDACi-induced replication
stress/DNA damage precedes apoptotic DNA fragmentation, which can also trigger the formation of
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catenin mRNA levels were n t decre d by LBH589 (data not shown). 
As LBH589 blocks class I, II, and IV HDACs [22], we addressed whether class I HDACs and/or
HDAC6 prevent th  processing of β-catenin. We inhibited H AC1-3 with MS-275 [22] and HDAC6
with marbostat-100 [26]. We noticed that MS-275 cau ed the cleavage of PARP  and β-catenin
toget er with an ctivation of caspase-3 in both cell es (Figure 2A). LBH589 and MS-275 also
prom ted an accumulation of   ɣ   H2AX indicating replication stress and/or DNA damag [21] in 
MV4-11 and HEL cells (Figur  2A). We could confirm [26] tha  LBH589 attenu tes the ex ress on f
HDAC6 in leukemic cells. Moreover, LBH589 as well as marbostat-100 effectively i hibit HDAC6
which is evident as ccumulation of acetylated tubulin [26,28,29]. Congruent with Figure 1A,B, 
marbostat-100 did not vok the ctivation of caspase 3 or the processing of β-catenin (Figur  2A).  
To exclude that the processing of β-cat nin in response to HDACi is an artifact of p rmanent
leukemic c ll cultures, we incubated the LTC FFM12 with LBH589. As in per anent cell lines
LBH589 led to a cleavage of β-catenin and PARP1 (Figure 2B). 
Next, we compared the β-catenin levels of MV4-11 and HEL cells with the β-catenin levels in 
normal PBMCs. We included colorect l ca cer cells with wild-type (RKO cells) or mutant β-catenin
(HCT116 cells) for comparison. We found a similar expression of β-catenin i  PBMCs, RKO, HEL
and MV4-11 cells. HCT116 cells showed the expected [56] ov rexpression of mutant β-cat nin (F gure
2C). These data suggest that β-catenin is wild-type in MV4-11 and HEL cells. 
We noted the occurrence of β-cat nin cleavage products in cells w th a high activi y of the
apoptosis executioner enzyme caspase-3 (Figure 2A), which can cleave β-catenin [16,17]. Therefore,
we speculated that caspases process β-catenin in AML cells exposed t  p o- poptotic dose  of
LBH589. We tested his hypothesis with the pan-caspase inhibitor z-VAD-FMK. Incubation of AML 
cells with LBH589 and z-VAD-FMK prevented the occurrenc of β-cate in cleavage oducts 
restored the levels of full-leng h β-catenin (Figure 2D). We observed similar d ta fo  MS-275 a d 
FK228 and the efficiency of z-VAD-FMK was proven as abrogated activ ion of ca ase-3 and intact
PARP1 (Supplementary Figure S3). 
To complement these analyses, w  tested for putative lterations of the expression and
phosphorylation-dependent activation of GSK3β, which promotes the proteasomal degradation of β-
cate in [15]. We noted that HDACi do not alter tot l and phosphorylated GSK3β in MV4-11 and
FFM12 cells (Figure 2B,D). 
LBH589, MS-275, and FK228 increased the levels of ɣH2AX and promoted apoptosis of MV4-11
cells (Figure 2A, and Supplementary Figure S3). DNA double strand breaks, which are gen rated
upon DNA f agmentati n by caspase-activated DN s , c n also induce ɣH2AX [57,58]. Therefor , 
such an accumulation of ɣH2AX might be a consequence of apoptotic DNA fragmentation. T  test 
this, we incubated MV4-11 cells with HDACi and z-VAD-FMK. We found that this accumulation of 
ɣH2AX could only be partially abrogated with z-VAD-FMK (Supplementary Figure S3). These data 
agree with previous reports indicating that HDACs are gatekeepers of genomic integrity [21,28,59–
61]. 
H2AX [57,58]. Others also report that a pharmacological interference with HDAC3 triggers replication
stress, DNA damage, cell death, and enhanced chemosensitivity of lymphocytic and myeloid leukemia
cells [59,60,63,65,69]. Such data are consistent with the reported impaired DNA repair capacities of
HDACi-treated leukemic cells [21,28,59–61,63,64,70].
As HDAC3 has functions that are dependent and independent of its catalytic activity [71] it is
important that RGFP966 phenocopies a genetic depletion of HDAC3 in transformed hematopoietic
cells [65]. Since up to 15 µM RGFP966 specifically inhibits HDAC3 [66], our experimental settings with
1–10 µM RGFP966 likely revealed specific functions of HDAC3 activity. Hence, targeting HDAC3
seems to be a promising strategy to decrease β-catenin, MYC, and WT1, and to eliminate leukemic cells
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through replication stress/DNA damage and apoptosis. Our flow cytometry data demonstrated that
RGFP966 decreased the numbers of cells in the G1 and G2/M phases dependent on caspases. The S
phase populations were not rescued though when z-VAD-FMK was applied with RGFP966. This also
applied to the accumulation of
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Since β-catenin is relevant for the growth and survival of leukemic cells [3–9], we tested whether 
LBH589 alters the expression of this protein in leukemic cells. Western blot analyses of MV4-11 and 
HEL cells revealed that β-catenin was significantly degraded after incubation with LBH589. This led 
to the advent of an additional band that was revealed by the β-catenin antibody (Figure 2A). The β-
catenin mRNA levels were not decreased by LBH589 (data not shown). 
As LBH589 blocks class I, II, and IV HDACs [22], we addressed whether class I HDACs and/or 
HDAC6 prevent the processing of β-catenin. We inhibited HDAC1-3 with MS-275 [22] and HDAC6 
with marbostat-100 [26]. We noticed that MS-275 caused the cleavage of PARP1 and β-catenin 
together with an activation of caspase-3 in both cell lines (Figure 2A). LBH589 and MS-275 also 
promoted an accumulation of   ɣ   H2AX indicating replication stress and/or DNA damage [21] in 
MV4-11 and HEL cells (Figure 2A). We could confirm [26] that LBH589 attenuates the expression of 
HDAC6 in leukemic cells. Moreover, LBH589 as well as marbostat-100 effectively inhibit HDAC6, 
which is evident as accumulation of acetylated tubulin [26,28,29]. Congruent with Figure 1A,B, 
marbostat-100 did not evoke the activation of caspase-3 or the processing of β-catenin (Figure 2A).  
To exclude that the processing of β-catenin in response to HDACi is an artifact of permanent 
leukemic cell cultures, we incubated the LTC FFM12 with LBH589. As in permanent cell lines, 
LBH589 led to a cleavage of β-catenin and PARP1 (Figure 2B). 
Next, we compared the β-catenin levels of MV4-11 and HEL cells with the β-catenin levels in 
normal PBMCs. We included colorectal cancer cells with wild-type (RKO cells) or mutant β-catenin 
(HCT116 cells) for comparison. We found a similar expression of β-catenin in PBMCs, RKO, HEL, 
and MV4-11 cells. HCT116 cells showed the expected [56] overexpression of mutant β-catenin (Figure 
2C). These data suggest that β-catenin is wild-type in MV4-11 and HEL cells. 
We noted the occurrence of β-catenin cleavage products in cells with a high activity of the 
apoptosis executioner enzyme caspase-3 (Figure 2A), which can cleave β-catenin [16,17]. Therefore, 
we speculated that caspases process β-catenin in AML cells exposed to pro-apoptotic doses of 
LBH589. We tested this hypothesis with the pan-caspase inhibitor z-VAD-FMK. Incubation of AML 
cells with LBH589 and z-VAD-FMK prevented the occurrence of β-catenin cleavage products and 
restored the levels of full-length β-catenin (Figure 2D). We observed similar data for MS-275 and 
FK228 and the efficiency of z-VAD-FMK was proven as abrogated activation of caspase-3 and intact 
PARP1 (Supplementary Figure S3). 
To complement these analyses, we tested for putative alterations of the expression and 
phosphorylation-dependent activation of GSK3β, which promotes the proteasomal degradation of β-
catenin [15]. We noted that HDACi do not alter total and phosphorylated GSK3β in MV4-11 and 
FFM12 cells (Figure 2B,D). 
LBH589, MS-275, and FK228 increased the levels of ɣH2AX and promoted apoptosis of MV4-11 
cells (Figure 2A, and Supplementary Figure S3). DNA double strand breaks, which are generated 
upon DNA fragmentation by caspase-activated DNase, can also induce ɣH2AX [57,58]. Therefore, 
such an accumulation of ɣH2AX might be a consequence of apoptotic DNA fragmentation. To test 
this, we incubated MV4-11 cells with HDACi and z-VAD-FMK. We found that this accumulation of 
ɣH2AX could only be partially abrogated with z-VAD-FMK (Supplementary Figure S3). These data 
agree with previous reports indicating that HDACs are gatekeepers of genomic integrity [21,28,59–
61]. 
H2AX, which was largely unaffected by z-VA -FMK. Therefore, we
concluded that S phase stalling and replication stress/DNA damage induction by RGFP966 was due
to a genuine induction of replication stress/DNA damage that halted cell cycle progression. Further
studies are underway to determine the targets of HDAC3 that control cellular responses to replication
stress and DNA damage and whether cells slip from G2/M phase to G1 phase or die out of G2/M phase
through mitotic catastrophe.
We further show that the extent of β-catenin processing by caspases tied in with a failure of
leukemic cells to recover from HDACi-induced stress. Accordingly, a destabilization of β-catenin with
indomethacin combined superiorly with HDACi. This finding could be due to the destabilization of
β-catenin by both HDACi and NSAIDs, but NSAIDs exert multiple effects [35,62,72,73]. However,
while several NSAIDs repress transcription factors of the NF-κB family, which can be a driver of
tumorigenesis in hematopoietic and solid tumor cells, indomethacin does not inactivate NF-κB, AP1, and
cancer-relevant kinases. Nonetheless, indomethacin activates PPAR
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length PARP1 and that the lot of the anti-PARP1 antibody may have preferentially recognized the 
cleaved form of PARP1. (D) Regrowth of the human leukemia cell lines MV4-11 and HEL. Cells were 
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2.2. Reduction of β-Catenin upon Class I HDAC Inhibition 
Since β-ca enin is relevant for the owth and survival of leukemic cells [3–9], we tested whether 
LBH589 alters th  expression of this protein in leukemic cells. Western blot analyses of MV4-11 and 
HEL cells revealed that β-catenin was ig ificantly degraded after incubation with LBH589. This led 
to the advent of an additional band that was evealed by the β-catenin antibody (Figure 2A). The β-
cate in m NA levels were not decreased by LBH589 (data not shown). 
As LBH589 blocks class I, II, and IV HDACs [22], w  addressed whether class I HDACs and/or 
HDAC6 p event the processing of β-cat nin. We inhibited HDAC1-3 with MS-275 [22] and HDAC6 
with m rbostat-100 [26]. We noticed that MS-275 caused the cleavage of PARP1 and β-catenin 
toge r with an activation of caspase-3 in both cell lines (Figure 2A). LBH589 and MS-275 also 
promote  an accumulation of   ɣ   H2AX indicating replication stress and/or DNA damage [21] in 
MV4-11 and HEL cells (Figure 2A). We could confirm [26] that LBH589 attenuates the expression of 
HDAC6 in leukemic cells. Moreover, LBH589 as well as marbostat-100 effectively inhibit HDAC6, 
which is evident as accumulati n of acetyl ted ubulin [26,28,29]. Congruent with Figure 1A,B, 
marbostat-100 did not evoke the activation of caspase-3 or the processing of β-catenin (Figure 2A).  
To exclud that th  processing of β- atenin in espon e to HDACi is an artifact of permanent 
leukemic cell cultures, we incubated the LTC FFM12 with LBH589. As in permanent cell lines, 
LBH589 led to a cleavage of β-c tenin and PARP1 (Figure 2B). 
Next, we compared the β-catenin levels of MV4-11 and HEL cells with the β-catenin levels in 
normal PBMCs. We includ d colorectal cancer c lls with wild-type (RKO cells) or mutant β-catenin 
(HCT116 cells) for comparison. We found a similar expression of β-catenin in PBMCs, RKO, HEL, 
and MV4-11 cells. HCT116 cells showed the expected [56] overexpression of mutant β-catenin (Figure 
2C). These data suggest that β-catenin is wild-type in MV4-11 and HEL cells. 
We not d the occurrence of β-catenin cleavage products in cells with a high activity of the 
apoptosis executioner enzyme caspas -3 (Figure 2A), which can cleave β-catenin [16,17]. Therefore, 
we speculated that casp ses process β-catenin in AML cells exposed to pro-apoptotic doses of 
LBH589. We t sted this hy thes s with the pan-caspase inhibitor z-VAD-FMK. Incubation of AML 
cells with LBH589 and z-VAD-FMK prevented the occurrence of β-catenin cleavage products and 
res ored e levels of full-length β-catenin (Figure 2D). We observed similar data for MS-275 and 
FK228 and the efficiency of z-VAD-FMK was proven as abrogated activation of caspase-3 and intact 
PARP1 (Supplementary Figure S3). 
To complement these analyses, we tested for putative alterations of the expression and 
phosphorylation-dependent activation of GSK3β, which promotes the proteasomal degradation of β-
catenin [15]. We noted that HDACi do not alter total and phosphorylated GSK3β in MV4-11 and 
FFM12 cells (Figure 2B,D). 
LBH589, MS-275, and FK228 increased the levels of ɣH2AX and promoted apoptosis of MV4-11 
cells (Figure 2A, and Supplementary Figure S3). DNA double strand breaks, which are generated 
upon DNA fragmentation by caspase-activated DNase, can also induce ɣH2AX [57,58]. Therefore, 
such an accumulation of ɣH2AX might be a consequence of apoptotic DNA fragmentation. To test 
this, we incubated MV4-11 cells with HDACi and z-VAD-FMK. We found that this accumulation of 
ɣH2AX could only be partially abrogated with z-VAD-FMK (Supplementary Figure S3). These data 
agree with previous reports indicating that HDACs are gatekeepers of genomic integrity [21,28,59–
61]. 
[74] and an activation of PPAR
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poptosis executioner enzyme casp se-3 (Figure 2A)  whic  can cl ave β-catenin [16,17]. Therefore, 
we pecul ted that caspases proces  β-catenin in AML cell  exposed to pro-apoptotic doses of 
LBH589. We tested thi  hypothesis with the pan-caspase i hibitor z-VAD-FMK. Incubation of AML 
cells wit  LBH589 and z-VAD-FMK pr ve ted the occurrence of β-catenin cleavage products and 
restored the levels of full-l ngth β-catenin (Figure 2D). We observed similar data for MS-275 and 
FK228 and the effic ency of z-VAD-FMK was proven as abrogated activation of caspase-3 and intact 
PARP1 (Supplementary Figure S3). 
To compl ment these analys s, we tested for putative alterations of the expression and 
phosphorylation-dependent ac ivation of GSK3β, which promotes the proteasomal degradation of β-
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by glitazones can attack the leukemic stem cell pool in CML [75]. Additional investigations are justified
to define the beneficial effects of NSAIDs on leukemic cells and their stem cells. This also applies to solid
tumor cells form breast, colon, lung, and prostate, for which bifunctional conjugates of indomethacin
with SAHA are potent inhibitors of growth and angiogenesis [35,36]. For example, compound 11b,
an indomethacin-SAHA fusion molecule that selectively inhibits COX2 and HDAC6 > HDAC8 >
HDAC3 > HDAC2 > HDAC1, inhibits the proliferation of androgen-dependent prostate carcinoma
cells [35]. Further studies may find a relevance of HDAC8 inhibition by this compound, because this
class I HDAC is also a valid target in AML cells [76]. The finding that compound 11b is effective
against cancer cells and selective for COX2 is promising because COX1 is a constitutively expressed
housekeeping enzyme while COX2 is induced upon infla mation [35]. Independent thereof is the
consensus that the anti-tumor effects of NSAIDs are not directly linked to their inhibitory effects on
COX1/COX2, but rather on other effects. These include among others the suppression of β-catenin and
aberrant WNT signaling [32,33,35,73].
Caspases -3, -6, -7, and -8 catalyze the degradation of β-catenin [16,17] in solid tumor cells and
in vitro. Our data collected with z-VAD-FMK suggest that caspases cleave β-catenin in HDACi-treated
leukemic cells. Consistent with this idea, we see β-catenin cleavage products with a similar size as the
ones seen by others under apoptotic conditions and caspase activation [16,17]. Further experiments
are necessary to decipher which caspases or other enzymes process β-catenin in leukemic cells and
why only a subset of HDACi-treated leukemic cells cleaves β-catenin.
We demonstrate that MYC and WT1 have an antagonistic relationship, with MYC activating
WT1 and WT1 suppressing MYC. We also show a regulation of β-catenin through WT1 in leukemic
cells. Data collected with kidney-, solid tumor-, and CML-derived cells coherently show that WT1
can repress the expression of MYC [47,48]. However, the opposite effect of WT1 on MYC has also
been reported in such cells [54,77]. Culture conditions as well as a context-dependent regulation
may explain such discrepancies. Moreover, different isoforms of WT1 can determine whether it has a
role as an oncogene or a tumor suppressor [49]. Our data illustrating an accumulation of β-catenin
upon a reduction of WT1 in leukemic cells corresponds to an observed negative i pact of WT1 on
β-catenin signaling in breast cancer cells [51], Sertoli cells forming the blood-testis barrier [50], and
podocytes within the kidney [52]. WT1 also impairs β-catenin/WNT signaling via other pathways
in vitro and in vivo [53], but one cannot exclude that there is a cell type-specific interplay between
β-catenin and WT1 [54]. It likewise remains to be clarified whether the mutual control of MYC and
WT1 has further implications, for example for their antagonistic effects on the cell cycle regulator
p21 [78,79]. The concomitant loss of all three transcription factors in HDACi-treated cells demonstrates
that an inhibition of HDACs, and particularly of HDAC3, overwrites such regulatory effects and leads
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to their loss by caspase-dependent and -independent mechanisms. Our data additionally suggest that
the reduction of MYC by HDACi may lead to a reduction of WT1 in leukemic cells, but not vice versa.
The elimination of β-catenin does not affect MYC and we see no mutual regulation of β-catenin
and MYC in leukemic cells. Accordingly, we found that MYC was decreased in HDACi-treated cells
irrespective of whether they retained β-catenin. While this lack of coregulation between β-catenin
and MYC is unexpected [11,39,40], others also found that an attenuation of β-catenin by BC2059 did
not affect MYC levels in leukemic cells [23]. Moreover, this work shows that a similar reduction of
β-catenin by LBH589 or BC2059 leads to either a clear or no reduction of MYC. Hence, LBH589 triggers
processes that decrease MYC largely independent of β-catenin. It is also possible that the wild-type or
mutant status of β-catenin has an impact on its relevance in cells and onto MYC expression. Our data
suggest that β-catenin is wild-type in the leukemic cell lines that we analyzed. This finding agrees with
the notion that only a subset of AML cases overexpresses β-catenin [4–6]. Moreover, an elimination of
β-catenin restricts the proliferation of a limited number of AML cells [11] and variable combination
indices resulted from LBH589/BC2059 cotreatment schedules in primary AML cells [23]. Furthermore,
a dysregulation of β-catenin in leukemic cells does not always imply their addiction to β-catenin [11].
This also holds true for colon cancer cells with mutant β-catenin [56] and β-catenin does not affect a
lethal growth of lymphoma in mice [10]. Likewise, if β-catenin was the only critical factor for leukemic
cell growth, indomethacin would be far more useful for leukemia treatment.
Our finding that single elimination of β-catenin, MYC, and WT1 does not kill MV4-11 cells may
equally hint that HDACi trigger complex apoptosis cascades that cannot be mimicked by a depletion
of one stemness-associated transcription factor. Furthermore, a remaining expression of β-catenin,
MYC, and WT1 may have ensured the survival of the investigated cells. Maybe a combined inhibition
and a more prolonged reduction of these factors halts cell proliferation. Such an idea is supported by
the finding that a CRISPR-Cas9-based deletion of β-catenin requires over 10 days to eliminate HEL
cells [39]. Since β-catenin cleavage products exert biologically important functions [16], it is equally
plausible that RNAi-mediated depletion cannot mimic the effect of HDACi-induced processing of
β-catenin in response to a treatment with HDACi. Moreover, other HDACi-triggered mechanisms,
including replication stress and DNA damage [21], may be more relevant inducers of cell death.
This idea agrees with the finding that HU also triggers the processing of β-catenin.
Remarkably, MYC is of predictive value for therapy success of AML patients who are treated
with HDACi [19] and we show that MYC is a target of RGFP966. Whether RGFP966 is useful in the
clinic remains to be resolved. In rodents, repetitive applications of RGFP966 were safe and produced
beneficial effects without toxicity to normal tissues [65,66,80]. Our data illustrate that a reduction of
MYC, irrespective of whether β-catenin is cleaved or not, is a good marker for apoptosis induction by
HDACi. In addition to the HDAC1/HDAC2-dependent transcriptional regulation of MYC in pancreatic
carcinoma cells [81], our data collected with RGFP966 suggest that HDAC3 supports the expression
of MYC in leukemic cells. Consistent with these data, others found that HDAC3 is necessary for the
growth of MYC-driven lymphoma [65]. Nonetheless, we cannot rule out that HDAC1 and HDAC2
maintain the expression of β-catenin, MYC, and WT1 in leukemic cells. Moreover, faster migrating
products of MYC in LBH589-treated HL60 AML cells suggest a possible proteolysis of MYC [23].
Irrespective thereof, the data that we collected with z-VAD-FMK suggest that HDACi decrease MYC
independent of caspase activation.
Regarding WT1, HDACi trigger a loss of the WT1 protein through an induction of the E2
ubiquitin conjugase UBCH8 and a shutdown of the WT1 promoter [46]. As recent data demonstrate
caspase-dependent processing of WT1 upon replication stress and DNA damage in leukemic cells [55,82],
caspases may as well degrade WT1 upon an inhibition of class I HDACs in leukemic cells. The details
on how HDACi alter the expression, stability, acetylation, and other posttranslational modifications of
β-catenin, MYC, and WT1 as well as the physiological consequences thereof should be analyzed in
future research.
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Taken together, our results show that a loss of β-catenin, MYC, and WT1 are molecular markers
for beneficial effects of HDACi. The data also suggest combining class I HDACi with indomethacin
against leukemic cells.
4. Materials and Methods
4.1. Cell Lines and Reagents
Human leukemic cell lines (MV4-11, HEL, and KG1) were from the German collection of
microorganisms and cell cultures. Cells were authenticated by DNA fingerprinting (DNA profiling
using eight different and highly polymorphic short tandems repeats) at the Leibniz-Institute (DSMZ,
Braunschweig, Germany). Leukemic cells grow at 37 ◦C and a 5% CO2 humidified atmosphere in
RPMI 1640 medium supplemented with 5%–10% fetal calf serum (FCS), and 1% penicillin/streptomycin
(Sigma-Aldrich, Taufkirchen, Germany). LBH589, MS-275, z-VAD-FMK, and RGFP966 were from
Selleckchem (Munich, Germany). Marbostat-100 was synthesized as described [26]. Annexin-V-APC
(#550474), 7AAD (#559925) and annexin-V binding buffer (#556454) were provided by BD Bioscience
(Heidelberg, Germany). Annexin-V-FITC was from Miltenyi Biotec (Bergisch-Gladbach, Germany),
propidium iodide (PI), HU, and indomethacin were from Sigma-Aldrich (Taufkirchen, Germany)
and z-VAD-FMK (#FMK001) was provided by R&D Systems (Wiesbaden, Germany). Isolation of
mononuclear cells and the subsequent immunomagnetic selection of CD34+ cells for establishment
of primary AML cell long-term cultures (LTCs) have been described, LTC FFM12 has a monosomy
of chromosome 7, and LTC FFM05 has a complex aberrant karyotype [41,83]. AML-LTCs cells were
maintained in X-Vivo-10 supplemented with 10% FCS (GE Healthcare HyClone™, München, Germany),
interleukin-3, thrombopoietin (25 ng/mL each), stem cell factor, and FLT3-ligand (50 ng/mL each,
Miltenyi, Bergisch-Gladbach, Germany) for 7 days. Peripheral blood mononuclear cells (PBMCs)
were isolated by Ficoll Histopaque®-1077 (Sigma-Aldrich, Taufkirchen, Germany) density gradient
centrifugation from buffy coats. Samples were from healthy donors at the blood bank of the University
Medical Center Mainz. PBMCs were washed thrice with PBS + 2 mM EDTA + 0.05% BSA and seeded in
RPMI 1640 medium containing 10% FCS and 1% penicillin/streptomycin. All cell lines and AML-LTCs
were confirmed to be free of mycoplasma every 1–2 months.
4.2. Apoptosis and Proliferation Assays
Since the experiments were conducted in different laboratories, two equally possible methods
were used. For the measurement of cell death rates and cell cycle distributions after 24 h treatments,
cells were analyzed as described by us [26,29,55]. For the measurements 48 h after treatments, cells
were stained using annexin-V-APC (#550474; apoptosis) and 7AAD (#559925; late apoptosis/necrosis)
according to the instructions of the manufacturer with annexin-V binding buffer (#556454; BD Bioscience,
Heidelberg, Germany) and analyzed by flow cytometry using LSRII or FACS Canto from BD Bioscience
(Heidelberg, Germany). For the regrowth assays, 15 × 104 cells/mL were seeded in 24-well plates and
treated with RGFP966 or LBH589. Cell numbers and viability of cells were determined at day 4 after
discontinuation of treatment by counting and the trypan blue dye exclusion test. Cells were harvested
by centrifugation and washed twice with PBS to remove HDACi.
4.3. Western Blotting and Immunofluorescence
Western blotting was done according to [29,55,84] and the antibodies: Abcam, Berlin, Germany:
Anti-HDAC3 (ab16047), anti-WT1 (ab89901), and anti-GAPDH (ab128915); BD Bioscience, Germany:
Anti-β-catenin (610153), and anti-poly(ADP)-ribosyltransferase-1 (PARP1) (556362); Cell Signaling
Technology, Frankfurt, Germany: Anti-β-actin (#4970), anti-cleaved caspase-3 (9661), anti-MYC
(5605), and anti-HDAC6 (7558); Millipore-Merck Darmstadt, Germany: Anti-acetyl-Histone H3
(06-599), anti-HDAC1 (05-100), and anti-γH2AX (05-636); Roche, Mannheim, Germany: Anti-PARP1
(#1835238001); Santa Cruz, Heidelberg, Germany: Anti-β-actin (sc-47778), anti-GSK3β (sc-81462),
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anti-HDAC2 (sc-7899), anti-HSP90 (sc-13119), anti-p-Ser9-GSK3β (sc-373800), and anti-vinculin
(sc-73614); Sigma-Aldrich, Darmstadt, Germany: Anti-acetyl-Tubulin (T7451). Densitometry was
performed with Image Studio Lite.
Immunofluorescence was performed using anti-53BP1 antibody (MAB3802); Millipore-Merck
Darmstadt, Germany with the methodology described in [70].
4.4. Real-Time PCR-TaqMan (qRT-PCR)
Total RNA and first strand DNA were obtained according to standard protocols. TaqMan-PCR
was performed in triplicate using ABI PRISM 7700 (Applied Biosystems, Darmstadt, Germany).
“Assays-on-demand” for β-catenin transcripts were used according to the manufacturer’s instructions
(Assay-ID: beta-Catenin-Hs01076483_m1; Applied Biosystems, Darmstadt, Germany). Sequence
detector software SDS 2.0 (Applied Biosystems, Carlsbad, USA) was used for data analysis.
CT values were exported into excel worksheets for calculation of fold changes using the
comparative CT method. The internal reference gene was GUS, oligonucleotides ENF1102
(GAAAATATGTGGTTGGAGAGCTCATT) and ENR1162 (CCGAGTGAAGATCCCCTTTTTA), and probe
ENPR1142 (Fam-CCAGCACTCGTCGGT GACTGTTCA-Tamra).
4.5. RNAi
For this genetic manipulation of cells, we used published protocols [29,55]. We used siRNAs at
the following concentrations: β-catenin (100 pmol; Cell Signaling Technology, Frankfurt, Germany,
#6225), MYC (100 pmol; Santa Cruz, Heidelberg, Germany, sc-29226), and WT1 (100 pmol; Santa Cruz,
Heidelberg, Germany, sc-36846). Cells were electroporated with Amaxa™ Nucleofector™ II device
using kit L (Lonza, Cologne, Germany, vca-1005) or with the Neon™ Transfection System (Invitrogen,
Carlsbad, CA, USA). Cells were analyzed 48 h after electroporation.
4.6. Statistics
Statistical analyses were performed with GraphPad Prism 6. Significance was determined with
indicated statistical tests. Asterisks are distributed by p-values (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; and
**** p ≤ 0.0001).
5. Conclusions
In conclusion, we demonstrated that low doses of LBH589, MS-275, FK228, and RGFP966 induced
apoptosis, replication stress/DNA damage, and a lasting growth arrest of AML cells. Thus, inhibition
of HDAC3 seems to be sufficient to compromise the genomic integrity and the survival of such cells.
A loss of the transcription factors β-catenin, MYC, and WT1 marks the efficacy of HDACi. HDAC3
activity is a key factor for the maintenance of the expression of these tumor- and stemness-associated
transcription factors in AML cells. RNAi-based loss-of-function approaches illustrate a previously
unidentified cross-regulation between β-catenin, MYC, and WT1 in leukemic cells. Furthermore, our
study suggests that the frequently used non-steroidal anti-inflammatory drug indomethacin potentiates
long-lasting anti-proliferative effects of HDACi.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/10/1436/s1,
Figure S1: Examples of dot plots collected by flow cytometry of MV4-11 and HEL cells, Figure S2: Apoptosis
induction in MV4-11 and HEL after LBH589 treatment, Figure S3: Effects of HDACi and z-VAD-FMK on β-catenin
status, caspase-3 cleavage, and the HDACi-induced accumulation of
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0.01; *** p ≤ 0.001; **** p ≤ 0.0001). (C) Cells were treated with 10 nM or 30 nM LBH589 for 24 h. 
Indicated proteins were detected via Western blot (cl., cleaved; fl., full-length) with HSP90 and β-actin 
as loading controls (n = 3). Please note that compared to HEL cells MV4-11 cells have far less full-
length PARP1 and that the lot of the anti-PARP1 antibody may have preferentially recognized the 
cleaved form of PARP1. (D) Regrowth of the human leukemia cell lines MV4-11 and HEL. Cells were 
treated with 10 nM or 30 nM LBH589 for 24 h. Thereafter, cells were washed twice with PBS and 
reseeded. Cells were stained with trypan blue and viable cells were counted after 4 days (n = 3; mean 
+ SD; one-way ANOVA; **** p ≤ 0.0001). 
2.2. Reduction of β-Catenin upon Class I HDAC Inhibition 
Since β-catenin is relevant for the growth and survival of leukemic cells [3–9], we tested whether 
LBH589 alters the expression of this protein in leukemic cells. Western blot analyses of MV4-11 and 
HEL cells revealed that β-catenin was significantly degraded after incubation with LBH589. This led 
to the advent of an additional band that was revealed by the β-catenin antibody (Figure 2A). The β-
catenin mRNA levels were not decreased by LBH589 (data not shown). 
As LBH589 blocks class I, II, and IV HDACs [22], we addressed whether class I HDACs and/or 
HDAC6 prevent the processing of β-catenin. We inhibited HDAC1-3 with MS-275 [22] and HDAC6 
with marbost t-100 [26]. We noticed that MS-275 caused the cleavage of PARP1 and β-catenin 
together with an activation of caspase-3 in both cell lines (Figure 2A). LBH589 and MS-275 also 
promoted an accumulation of   ɣ   H2AX indicating replication stress and/or DNA damage [21] in 
MV4-11 and HEL cells (Figure 2A). We could confirm [26] that LBH589 attenuates the expression of 
HDAC6 in leukemic cells. Moreover, LBH589 as well as marbostat-100 effectively inhibit HDAC6, 
which is evident as accumulation of acetylated tubulin [26,28,29]. Congruent with Figure 1A,B, 
marbostat-100 did not evoke the activation of caspase-3 or the processing of β-catenin (Figure 2A).  
To exclude that the processing of β-catenin in response to HDACi is an artifact of permanent 
leukemic cell cultures, we incubated the LTC FFM12 with LBH589. As in permanent cell lines, 
LBH589 led to a cleavage of β-catenin and PARP1 (Figure 2B). 
Next, we compared the β-catenin levels of MV4-11 and HEL cells with the β-catenin levels in 
normal PBMCs. We included colorectal cancer cells with wild-type (RKO cells) or mutant β-catenin 
(HCT116 cells) for comparison. We found a similar expression of β-catenin in PBMCs, RKO, HEL, 
and MV4-11 cells. HCT116 cells showed the expected [56] overexpression of mutant β-catenin (Figure 
2C). These data suggest that β-catenin is wild-type in MV4-11 and HEL cells. 
We noted the occurrence of β-catenin cleavage products in cells with a high activity of the 
apoptosis executioner enzyme caspase-3 (Figure 2A), which can cleave β-catenin [16,17]. Therefore, 
we speculated that caspases process β-catenin in AML cells exposed to pro-apoptotic doses of 
LBH589. We tested this hypothesis with the pan-caspase inhibitor z-VAD-FMK. Incubation of AML 
cells with LBH589 and z-VAD-FMK prevented the occurrence of β-catenin cleavage products and 
restored the levels of full-length β-catenin (Figure 2D). We observed similar data for MS-275 and 
FK228 and the efficiency of z-VAD-FMK was proven as abrogated activation of caspase-3 and intact 
PARP1 (Supplementary Figure S3). 
To complement these analyses, we tested for putative alterations of the expression and 
phosphorylation-dependent activation of GSK3β, which promotes the proteasomal degradation of β-
catenin [15]. We noted that HDACi do not alter total and phosphorylated GSK3β in MV4-11 and 
FFM12 cells (Figure 2B,D). 
LBH589, MS-275, and FK228 increased the levels of ɣH2AX and promoted apoptosis of MV4-11 
cells (Figure 2A, and Supplementary Figure S3). DNA double strand breaks, which are generated 
upon DNA fragmentation by caspase-activated DNase, can also induce ɣH2AX [57,58]. Therefore, 
such an accumulation of ɣH2AX might be a consequence of apoptotic DNA fragmentation. To test 
this, we incubated MV4-11 cells with HDACi and z-VAD-FMK. We found that this accumulation of 
ɣH2AX could only be partially abrogated with z-VAD-FMK (Supplementary Figure S3). These data 
agree with previous reports indicating that HDACs are gatekeepers of genomic integrity [21,28,59–
61]. 
H2AX, Figure S4: Flow cytometry assessing
effects of LBH589 on KG1 cells, Figure S5: LB 589 is effective in FFM12 cells, Figure S6: Examples of dot plots
collected by flow cytometry of RGFP966-treated MV4-11 cells, Figure S7: HU decreases β-catenin and MYC,
Figure S8: Full scans of Western blot data.
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